

Review Article

A Review of Malaysian Herbal Plants and Their Active Constituents with Potential Therapeutic Applications in Sepsis

Kong Yen Liew , Md Faizul Hafiz , Yi Joong Chong , Hanis Hazeera Harith ,
Daud Ahmad Israf , and Chau Ling Tham 

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia

Correspondence should be addressed to Chau Ling Tham; chauling@upm.edu.my

Received 28 May 2020; Revised 28 September 2020; Accepted 1 October 2020; Published 28 October 2020

Academic Editor: Jenny M. Wilkinson

Copyright © 2020 Kong Yen Liew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis refers to organ failure due to uncontrolled body immune responses towards infection. The systemic inflammatory response triggered by pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) from Gram-negative bacteria, is accompanied by the release of various proinflammatory mediators that can lead to organ damage. The progression to septic shock is even more life-threatening due to hypotension. Thus, sepsis is a leading cause of death and morbidity globally. However, current therapies are mainly symptomatic treatment and rely on the use of antibiotics. The lack of a specific treatment demands exploration of new drugs. Malaysian herbal plants have a long history of usage for medicinal purposes. A total of 64 Malaysian plants commonly used in the herbal industry have been published in Malaysian Herbal Monograph 2015 and Globinmed website (<http://www.globinmed.com/>). An extensive bibliographic search in databases such as PubMed, ScienceDirect, and Scopus revealed that seven of these plants have antiseptic properties, as evidenced by the therapeutic effect of their extracts or isolated compounds against sepsis-associated inflammatory responses or conditions in *in vitro* or/and *in vivo* studies. These include *Andrographis paniculata*, *Zingiber officinale*, *Curcuma longa*, *Piper nigrum*, *Syzygium aromaticum*, *Momordica charantia*, and *Centella asiatica*. Among these, *Z. officinale* is the most widely studied plant and seems to have the highest potential for future therapeutic applications in sepsis. Although both extracts as well as active constituents from these herbal plants have demonstrated potential antiseptic activity, the activity might be primarily contributed by the active constituent(s) from each of these plants, which are andrographolide (*A. paniculata*), 6-gingerol and zingerone (*Z. officinale*), curcumin (*C. longa*), piperine and peltorine (*P. nigrum*), biflorin (*S. aromaticum*), and asiaticoside, asiatic acid, and madecassoside (*C. asiatica*). These active constituents have shown great antiseptic effects, and further investigations into their clinical therapeutic potential may be worthwhile.

1. Introduction

The term sepsis was historically used to describe rotting flesh or putrefaction [1]. In the current medical context, sepsis refers to a condition in which dysregulated immune responses towards infection lead to organ failure [2]. Sepsis may develop secondarily to bacterial, viral, fungal, or parasitic infections [3]. At present, the terms “sepsis” and “severe sepsis” are used interchangeably, whereas “septic shock” refers to a subset of sepsis which is associated with circulatory and metabolic abnormalities and thus increased risk of mortality [4].

Sepsis can be triggered by infectious agents or certain molecules they express, also known as pathogen-associated molecular patterns (PAMPs) [3]. The pathogens or PAMPs may cause direct toxicity and injury to tissues, but in the context of sepsis, the underlying damage is primarily attributed to the immune responses [5]. The exposure of immune cells to PAMPs, such as lipopolysaccharide (LPS), will trigger numerous responses in the body, including vasodilation to increase recruitment of immune cells, followed by rapid production of cytokines by activated immune cells to eradicate the invading pathogens [6]. While such cellular responses are required to remove the pathogens, the

same responses could also lead to profound disturbance and harm to the host. Vasodilation may subsequently lead to shock, whereas the cytokine storm may cause tissue damage and eventually leads to organ dysfunction and failure [7]. It is, in essence, a form of “friendly fire” that arises from the body’s attempt to eradicate the pathogens.

Despite the long history of sepsis, a significant improvement in its morbidity and mortality rate is yet to be observed. Sepsis was estimated to affect 30 million people worldwide, with up to 8 million fatalities each year [8]. In fact, the number of fatalities is expected to be greater since the epidemiological data on sepsis incidence and mortality rates from low- to middle-income countries was scarce [9]. In the United States alone, an estimated 1.7 million of sepsis cases occur among adults, resulting in more than 250 000 deaths each year [10]. Despite advancement in the healthcare system, the incidence of sepsis and associated mortality in the United States hospitals remained high from 2009 to 2014 [11]. The disease burden of sepsis is immense due to the enormous amount of healthcare costs spent [8].

In Malaysia, sepsis is a major cause of morbidity and mortality, particularly among ICU patients. In 2016 and 2017, sepsis was the most common diagnosis leading to ICU admission. Furthermore, in-hospital mortality rate following ICU admission due to sepsis also recorded an astonishing figure—more than 50% for six consecutive years since 2012 [12]. An eight-year review of blood culture from sepsis cases in the Emergency Department in a Malaysia hospital revealed that 55.2% of the isolated organisms were Gram-negative bacteria. The bacteria were also found to be more resistant to antibiotics commonly prescribed in the outpatient setting [13]. These findings highlight an urgent need to reduce the burden caused by sepsis both in Malaysia and worldwide.

2. Molecular Mechanisms in the Pathogenesis of Sepsis

Sepsis could be caused by bacterial, viral, fungal, or parasitic infections [3]. It is initiated when the initial host response to an infection becomes amplified and dysregulated, resulting in the loss of the balance between proinflammatory and anti-inflammatory responses [14, 15]. The recognition of PAMPs, such as bacterial endotoxins and fungal β -glucans, by pathogen recognition receptors (PRRs) expressed by the immune cells is considered the first event that triggers the innate immune responses [16, 17]. Innate immunity reacts immediately to the invading pathogens and thus plays a major role in the initiation of sepsis [15]. The binding of LPS, a well-recognized PAMP on the outer cell wall of Gram-negative bacteria, to toll-like receptor 4 (TLR4) will activate intracellular signaling pathways that promote the production of inflammatory mediators such as cytokines, chemokines, and nitric oxide (NO) [7, 16]. This is mainly mediated by the transcription factor nuclear factor- κ B (NF- κ B) that plays a crucial role in modulating inflammation by activating the transcription of various proinflammatory cytokines [16].

The vast array of inflammatory cytokines released during sepsis include proinflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-12, tissue necrosis factor (TNF)- α , interferon (IFN)- γ , and macrophage migration inhibitory factor (MIF) and anti-inflammatory cytokines, such as IL-10, IL-14, and transforming growth factor (TGF)- β . The uncontrolled release of these cytokines, which can damage tissue and organ by triggering inflammatory cascade, presents a major threat to sepsis patients [7]. Another important proinflammatory cytokine—high mobility group box (HMGB)-1, is a late phase mediator of sepsis. Its production is regulated by NF- κ B activation, but the exact mechanism still remains unclear [18]. HMGB-1 has pleiotropic effects on different immune cells, triggering the release of proinflammatory cytokines from peripheral blood mononuclear cells and endothelial cells, as well as inducing the maturation of dendritic cells [19]. Besides that, sepsis is also linked to prostaglandins (PGs), which are lipid mediators produced by cyclooxygenase (COX) enzyme in response to inflammation or infection [20]. Since PGs are involved in various unfavorable outcomes of sepsis, such as impaired tissue perfusion and organ failure, COX inhibitors targeting the inducible form of COX (COX-2) had been tested clinically, but none of the studies reported a promising outcome [21].

Apart from causing organ damage, inflammatory mediators could also cause injury on the endothelial lining of the blood vessels, leading to endothelial dysfunction—a common feature of both sepsis and septic shock [16]. Endothelial dysfunction is accompanied by increased permeability, which could lead to vascular leakage and subsequently life-threatening conditions due to edema and hypotension [22]. Under normal physiological condition, NO is produced by endothelial cells using the constitutively expressed form of the nitric oxide synthase (NOS) enzyme. However, excessive production of NO by the inducible form of NOS (iNOS) was found to contribute to hypotension and vascular abnormalities in patients with septic shock [23]. Damaged endothelial cells also release tissue factors that may activate a coagulation cascade which in turn could disturb the homeostatic balance in sepsis patients [17].

Collectively, the processes described above indicate the complex nature of sepsis which involves the interaction between different types of immune responses and mediators. This complexity that underlies sepsis may partly explain why the development of an effective treatment for sepsis is challenging.

3. An Unmet Need for Sepsis-Specific Treatment

Despite the attention and research interest sepsis has received, FDA-approved drugs to treat sepsis are still lacking. The current guideline for the treatment of sepsis is centered loosely on the Surviving Sepsis Campaign. The campaign was launched in 2004 [24] and updated every four years [2, 25, 26], including a revised bundle developed as an update to the 2016 edition [27]. The campaign defined numerous treatment procedures and methods to deal with

sepsis patients, which mainly emphasize initial resuscitation, early diagnosis, and antimicrobial therapy [2].

The Surviving Sepsis Campaign had yielded positive outcome in the survival rate of sepsis patients; however, the mortality rate remained high at 27.2% and 36.7% for ICU and in-hospital patients, respectively [28]. One possible reason could be the lack of a sepsis-specific treatment that targets the hyperinflammatory state of the patients. As described earlier, sepsis is a hyperinflammatory disease, with pathogen as the causative agent. While eradication of the pathogen using antimicrobial therapy may be effective in reducing the mortality rate of sepsis, a combined therapy with anti-inflammatory agents may further improve the survival rate of sepsis patients. Nevertheless, another challenge to pursue this alternative is the fact that anti-inflammatory drug specific for sepsis is lacking.

In order to develop drugs for the treatment of sepsis, several strategies which specifically target sepsis-associated cytokines, inflammatory enzymes, or the coagulation cascade have been attempted. These include TNF- α inhibitor [29], TNF receptor p55 inhibitor [30], IL-1 inhibitor [31], anticoagulant therapy [32], and nitric oxide synthase inhibitor [33], but none of these enhanced the survival rate of sepsis patients. Nevertheless, a recombinant form of human activated protein C, drotrecogin alfa (activated), was approved by FDA in 2001 for the treatment of severe sepsis after it was demonstrated to improve the patients' survival rate in the PROWESS trial [34]. However, drotrecogin alfa (activated) was later withdrawn from the market in 2011 after the follow-up PROWESS SHOCK trial failed to replicate the promising results reported earlier [35]. On the contrary, the advantage of using corticosteroids remains elusive as a recent meta-analysis revealed that the use of corticosteroids in critically ill patients with sepsis possibly results in a small reduction in mortality but, at the same time, also possibly increases the risk of neuromuscular weakness [36]. Two other drugs, thrombomodulin alfa (ART-123) and toraymyxin, are currently in phase III clinical trials, while several others are yet to reach phase III [37].

Prior to entering clinical trials, potential therapeutic agents for sepsis would be evaluated for their efficacy in the preclinical studies using different experimental models. Sepsis animal models are generally divided into three categories: endotoxemia model (e.g., LPS infusion), bacterial infection model (e.g., *Escherichia coli* infusion), and host-barrier disruption model (e.g., cecal ligation and puncture (CLP) and colon ascendens stent peritonitis (CASP)) [38]. For LPS-induced endotoxemia, the animals are occasionally presensitized with D-galactosamine to reduce the dose of LPS required to generate an inflammatory response [39]. CLP-induced polymicrobial sepsis is currently the most widely used model due to its close resemblance to the progression and clinical characteristics of human sepsis [40]. Despite showing efficacy in the preclinical studies, many therapies have failed to produce a promising outcome in the clinical settings [38].

Taken together, the lack of a specific antiseptic treatment is still an unresolved issue and thus highlights the need to

prioritize the exploration of new drugs. This is particularly important as the continuous use of antibiotic therapy to treat sepsis may promote antibiotic resistance which will be another great challenge for healthcare professionals.

4. Insights into Malaysian Herbal Plants

Given the unsuccessful attempts on the development of drugs for sepsis treatment so far, it may be worthwhile to explore other alternatives such as herbal-based medicine. Herbal-based medicine has increasingly gained attention since Professor Tu Youyou was awarded a Nobel Prize in Physiology or Medicine in 2015 for her discovery of artemisinin as a treatment for malaria. Artemisinin was actually discovered through the screening of herbs based on ancient manuscripts [41]. Thus, it is highly encouraging that herbal-based medicine may have the potential to be further developed for the treatment of sepsis.

Malaysia is a country rich in flora and fauna, with diverse culture and practices influenced mainly by Malay, Chinese, and Indian backgrounds. Hence, various plants in Malaysia have been used for medicinal purposes based on different cultures and practices [42]. This review aims to provide detailed information of some Malaysian herbs that may have the potential to treat sepsis.

5. Methodology

A total of 64 herbal plants were documented in Malaysian Herbal Monograph 2015 (See Supplementary Material-Table A), which extensively describes their traditional uses and proven pharmacological activities. Such information is also available online in the Globinmed website (<http://www.globinmed.com/>), created by Institute for Medical Research under Ministry of Health Malaysia. A bibliographic search was performed in the following databases: PubMed, ScienceDirect, and Scopus, to find any sepsis-related study on each of the 64 herbal plants listed in Malaysian Herbal Monograph 2015. The search terms used were ("scientific name of the plant" or "common name of the plant") and ("sepsis" or "lipopolysaccharide" or "LPS") without narrowing or limiting search items, and the last search was performed on 4 March 2020. All publications obtained from the databases with the searching criteria were studied. Herbal plants that have not been tested, either in the form of extracts or compounds isolated from the plants, in any sepsis-related study were excluded. Table 1 summarizes seven Malaysian herbal plants that have been studied for antiseptic properties, evidenced by the therapeutic effect of the extracts or compounds extracted from these plants against sepsis-associated inflammatory responses or conditions in *in vitro* or/and *in vivo* experimental models. These mainly include LPS- and LPS-/IFN- γ -induced macrophages (*in vitro*) and *E. coli*-infected mice, LPS-induced endotoxemia, and CLP-induced polymicrobial sepsis (*in vivo*). Besides that, *in vitro* or *in vivo* studies that used HMGB-1 or Transforming Growth Factor-Beta-Induced Protein (TGFBIp) as an inducer to induce endothelial barrier dysfunction were also included. This is because endothelial

TABLE 1: Malaysian herbal plants and their active constituents with potential therapeutic applications in sepsis.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Positive drug control	References
			Ethyl acetate extract (2–10 µg/mL), pretreatment (1 hr)	(i) Inhibits NO and PGE ₂ production (ii) Inhibits NF-κB transcriptional activity in LPS-/IFN-γ-induced macrophages	Helenalin, NF-κB inhibitor (10 µM), pretreatment (1 hr)	[43]
		<i>In vitro</i>	Ethyl acetate extract (2.5–20 µg/mL), pretreatment (1 hr)	(i) Decreases NO, MIP-2, TNF-α, and IL-6 production in LPS-/IFN-γ-induced macrophages (ii) Reduces endothelial permeability (iii) Inhibits CAMs expression (iii) Suppresses monocyte adhesion and transmigration (iv) Inhibits TNF-α and IL-1β production in HMGB-1-induced HUVECs	Helenalin, NF-κB inhibitor (10 µM), pretreatment (1 hr)	[44]
			Andrographolide (1–10 µM), posttreatment (6 hr)	(i) Improves survival rate (ii) Reduces serum levels of TNF-α, MIP-2, and NO in LPS-induced mice	Emodin-6-O-β-D-glucoside (EG) (10 µM), posttreatment (6 hr)	[45]
<i>Andrographis paniculata</i> (hempeđu bumi)	Acanthaceae		Ethyl acetate extract (0.78–3.12 mg/kg) via oral administration, daily for one week before LPS challenge	(i) Inhibits HMGB-1 production (ii) Decreases vascular permeability (iii) Suppresses leukocytes and neutrophils migration	Pyrrrolidine dithiocarbamate (PDTC), NF-κB inhibitor (50 mg/kg) via intraperitoneal injection, 1 hr before LPS stimulation	[44]
			Andrographolide (3.5–7.0 µg/mouse) via intravenous injection 16 hr after the CLP procedure	(iv) Improves survival rate in CLP-induced mice	Emodin-6-O-β-D-glucoside (EG) (9.0 µg/mouse) via intravenous injection 16 hr after the CLP procedure	[45]
		<i>In vivo</i>	Andrographolide (1–10 mg/kg) via intraperitoneal injection 10 min after LPS challenge	(i) Attenuates ALI (ii) Reduces TNF-α, IL-1β, and IL-6 levels in BALF (iii) Inhibits NF-κB activation and its DNA binding activity in LPS-induced mice	NA	[46]
			Andrographolide (2.5–10 mg/kg) via intraperitoneal injection 1 hr after LPS/D-galactosamine challenge	(i) Attenuates acute liver injury (ii) Reduces serum levels of ALT and AST (iii) Inhibits hepatic TNF-α and IL-1β production (iv) Inhibits NF-κB activation in LPS/D-galactosamine-induced mice	NA	[47]

TABLE 1: Continued.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Positive drug control	References
			Alcoholic ginger extract (1 μ L/mL), cotreatment (24 hr)	(i) Inhibits production of proinflammatory cytokines (IL-1 β , IL-12, and TNF- α) (ii) Inhibits production of chemokines (RANTES and MCP-1) in LPS-induced macrophages and MCP-1 in LPS-induced macrophages (iii) Inhibits production of proinflammatory cytokines (IL-1 β , IL-12, and TNF- α) (iv) Inhibits production of chemokine (RANTES) in LPS-induced macrophages (v) Inhibits endothelial hyperpermeability (vi) Suppresses expression of CAMs (ICAM and VCAM) (vii) Reduces adhesion and migration of neutrophils in HMGB-1-induced HUVECs	NA	[48]
			6-Gingerol (1 μ g/mL), cotreatment (24 hr)	(i) Inhibits production of proinflammatory cytokines (IL-1 β , IL-12, and TNF- α) (ii) Inhibits production of chemokine (RANTES) in LPS-induced macrophages (iii) Inhibits endothelial hyperpermeability (iv) Suppresses expression of CAMs (ICAM and VCAM) (v) Reduces adhesion and migration of neutrophils in HMGB-1-induced HUVECs	NA	[49]
	<i>In vitro</i>		Zingerone (10–50 μ M), posttreatment (6 hr)	(i) Inhibits adhesion and migration of neutrophils in HMGB-1-induced HUVECs (ii) Inhibits endothelial hyperpermeability (iii) Suppresses expression of CAMs (ICAM and VCAM) (iv) Reduces adhesion and migration of neutrophils in TGF β 1-induced HUVECs	NA	[50]
			Zingerone (10–50 μ M), posttreatment (6 hr)	(i) Inhibits adhesion and migration of neutrophils in TGF β 1-induced HUVECs (ii) Decreases IL-6 and IFN- γ production (iii) Inhibits iNOS and COX-2 expression in LPS-induced mice (iv) Attenuates liver injury (v) Decreases serum levels of ALT and AST (vi) Reduces serum level of IL-1 β in CLP-induced mice	NA	[51]
<i>Zingiber officinale</i> (halia)	Zingiberaceae		Dried ginger extract dissolved in distilled water (100–1000 mg/kg) via oral administration for 3 days before LPS challenge	(i) Inhibits adhesion and migration of neutrophils in TGF β 1-induced HUVECs (ii) Decreases IL-6 and IFN- γ production (iii) Inhibits iNOS and COX-2 expression in LPS-induced mice (iv) Attenuates liver injury (v) Decreases serum levels of ALT and AST (vi) Reduces serum level of IL-1 β in CLP-induced mice	NA	[52]
			6-Gingerol (40 mg/kg) via intragastric administration for 5 days before the CLP procedure	(i) Improves survival rate (ii) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in CLP-induced mice (iii) Improves survival rate (iv) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in TGF β 1-induced CLP mice	NA	[53]
			Zingerone (0.36 and 0.72 mg/kg) via intravenous injection 12 hr and 50 hr after the CLP procedure	(i) Improves survival rate (ii) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in CLP-induced mice (iii) Improves survival rate (iv) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in TGF β 1-induced CLP mice	NA	[50]
	<i>In vivo</i>		Zingerone (0.36 and 0.72 mg/kg) via intravenous injection 12 hr and 50 hr after TGF β 1 injection	(i) Improves survival rate (ii) Alleviates tissue injury (renal, hepatic, and pulmonary injury) in TGF β 1-induced CLP mice (iii) Attenuates ALI (iv) Reduces serum levels of TNF- α and IL-1 β in LPS-induced mice (v) Decreases serum levels of blood urea nitrogen (BUN) and creatinine (vi) Attenuates kidney injury (vii) Reduces levels of IL-1 β , IL-6, and TNF- α in the serum and kidney tissue in LPS-induced mice	NA	[51]
			Zingerone (10–40 mg/kg) via intragastric administration 1 hr before LPS challenge	(i) Attenuates ALI (ii) Reduces serum levels of TNF- α and IL-1 β in LPS-induced mice (iii) Decreases serum levels of blood urea nitrogen (BUN) and creatinine (iv) Attenuates kidney injury (v) Reduces levels of IL-1 β , IL-6, and TNF- α in the serum and kidney tissue in LPS-induced mice	Dexamethasone (5 mg/kg) via intragastric administration 1 hr before LPS challenge	[54]
			Zingerone (10–40 mg/kg) via intraperitoneal injection 1 hr after LPS challenge	(i) Attenuates ALI (ii) Reduces serum levels of TNF- α and IL-1 β in LPS-induced mice (iii) Decreases serum levels of blood urea nitrogen (BUN) and creatinine (iv) Attenuates kidney injury (v) Reduces levels of IL-1 β , IL-6, and TNF- α in the serum and kidney tissue in LPS-induced mice	Viral inhibitory peptide for TLR4 (VIPER) (0.1 mg/kg) via intravenous injection 2 hr before LPS challenge	[55]

TABLE 1: Continued.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Positive drug control	References
		<i>In vitro</i>	<i>C. longa</i> extract-loaded nanoemulsion (CLEN) (5 µg/mL), cotreatment (24 hr)	(i) Inhibits NO production (ii) Suppresses HMGB-1 release (iii) Inhibits iNOS expression in LPS-stimulated macrophages	NA	[56]
			CLEN (50 mg/kg) via intraperitoneal injection together with LPS challenge	(i) Improves survival rate in LPS-induced mice (ii) Improves survival rate (iii) Reduces levels of tissue injury markers (ALT, AST, and lactate)	NA	[56]
			Curcumin (3.5 µmol/kg) via intravenous injection 5 hr after the CLP procedure	(iii) Decreases TNF-α level in CLP-induced mice (i) Improves survival rate (ii) Attenuates blood-brain barrier dysfunction (iii) Inhibits leukocytes and platelets adhesion in CLP-induced mice	NA	[57]
			Curcumin (100 mg/kg) via intraperitoneal injection for 48 hr before the CLP procedure	(i) Improves survival rate (ii) Attenuates blood-brain barrier dysfunction (iii) Inhibits leukocytes and platelets adhesion in CLP-induced mice	NA	[58]
<i>Curcuma longa</i> (kunyit)	Zingiberaceae	<i>In vivo</i>	Curcumin (10 mg/kg) via intranasal administration 1 hr before LPS instillation	(i) Attenuates ALI (ii) Decreases NO and TNF-α levels (iii) Inhibits vascular leakage in LPS-induced mice	Dexamethasone (5 mg/kg) via intraperitoneal injection 1 hr before LPS instillation	[59]
			Curcumin (200 mg/kg) via intraperitoneal injection 30 min before LPS challenge	(i) Attenuates ALI (ii) Reduces TNF-α, IL-6, and MIP-2 levels in BALF in LPS-induced mice	NA	[60]
			Curcumin (20–80 mg/kg) via oral administration daily for 4 weeks before LPS challenge	(i) Inhibits production of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) (ii) Prevents liver failure in LPS-induced mice (iii) Improves survival rate	NA	[61]
			Curcumin (20 mg/kg) via intraperitoneal injection 1 hr before LPS challenge	(ii) Decreases the levels of TNF-α and inflammatory cells in BALF in LPS-induced mice	Dexamethasone (1 mg/kg) via intraperitoneal injection 1 hr before LPS challenge	[62]
			Curcumin (200 mg/kg/day) via intragastric administration for 3 days	(i) Attenuates cardiac dysfunction in CLP-induced mice	NA	[63]
			Curcumin (50–100 mg/kg) via intraperitoneal injection 3 hr before or after LPS challenge	(i) Improves vascular function (ii) Maintains normal heart rate (iii) Restores normal arterial blood pressure in LPS-induced mice	NA	[64]

TABLE 1: Continued.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Positive drug control	References
			Ethanol extract (NA)	(i) Inhibits NO production in LPS stimulated macrophages (ii) Inhibits IL-1 β production (iii) Inhibits HMGB-1 production in LPS-stimulated macrophages	NA	[65]
		<i>In vitro</i>	Piperine (20–80 μ M), pretreatment (4 hr)	(i) Reduces endothelial permeability (ii) Inhibits CAMs expression (iii) Suppresses leukocytes adhesion and migration in HMGB-1-induced HUVECs	NA	[66]
			Pellitorine (3–20 μ M), pretreatment (6 hr)	(i) Improves survival rate (ii) Inhibits TNF- α production in LPS-induced mice	Emodin-6-O- β -D-glucoside (EG) (10 μ M), pretreatment (6 hr)	[67]
			Piperine (1 and 5 mg/kg) via intraperitoneal injection 1 hr before LPS challenge	(i) Reduces serum and BALF levels of IL-1 β (ii) Reduces pro-IL-1 β and IL-1 β protein levels in colonic tissue in <i>E. coli</i> -infected mice (i) Attenuates ALI (ii) Reduces IL-1 β , IL-6, and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	NA	[68]
<i>Piper nigrum</i> (lada hitam)	Piperaceae		Piperine (20 mg/kg) via intragastric administration for 5 days before <i>E. coli</i> injection	(i) Improves survival rate (ii) Reduces vascular permeability (iii) Inhibits CAMs expression (iv) Inhibits leukocytes adhesion and migration in HMGB-1-induced mice	Emodin-6-O- β -D-glucoside (EG) (9.0 μ g/mouse) via intravenous injection 6 hr before HMGB-1 challenge	[67]
		<i>In vivo</i>	Piperine (15–60 mg/kg) via intraperitoneal injection 1 hr after LPS challenge	(i) Inhibits PGE ₂ production in LPS-induced macrophages (ii) Inhibits IL-1 β , IL-6, and IL-10 production in LPS-induced macrophages (i) Inhibits NO, PGE ₂ , IL-6, and TNF- α production (ii) Inhibits iNOS and COX-2 expression in LPS-stimulated macrophages (i) Inhibits lung inflammation in LPS-induced mice	NA	[69]
			Pellitorine (4.5–9.0 μ g/mouse) via intravenous injection 6 hr before HMGB-1 challenge	(i) Improves survival rate (ii) Reduces vascular permeability (iii) Inhibits CAMs expression (iv) Inhibits leukocytes adhesion and migration in HMGB-1-induced mice	Emodin-6-O- β -D-glucoside (EG) (9.0 μ g/mouse) via intravenous injection 6 hr before HMGB-1 challenge	[67]
			Methanol extract (10 μ g/mL), cotreatment (9–24 hr)	(i) Inhibits PGE ₂ production in LPS-induced macrophages	NA	[70]
		<i>In vitro</i>	Methanol extract (100 μ g/well), pretreatment (2 hr) and posttreatment (22 hr)	(i) Inhibits NO, PGE ₂ , IL-6, and TNF- α production (ii) Inhibits iNOS and COX-2 expression in LPS-stimulated macrophages	Dexamethasone (100 μ M)	[71]
			Biflorin (15–60 μ M), pretreatment (1 hr)	(i) Inhibits NO, PGE ₂ , IL-6, and TNF- α production (ii) Inhibits iNOS and COX-2 expression in LPS-stimulated macrophages	L-NIL (20 μ M) and NS-398 (3 μ M), pretreatment (1 hr)	[72]
<i>Syzygium aromaticum</i> (bunga cengkih)	Myrtaceae		Aqueous extract (200 mg/kg) via intraperitoneal injection for 2 days before LPS challenge	(i) Improves survival rate (ii) Reduces TNF- α production (iii) Inhibits iNOS and COX-2 expression in LPS-induced mice	NA	[73]
		<i>In vivo</i>	Biflorin (5 and 10 mg/kg) via intraperitoneal injection 1 hr before LPS challenge	(i) Improves survival rate (ii) Reduces TNF- α production (iii) Inhibits iNOS and COX-2 expression in LPS-induced mice	NA	[72]

TABLE 1: Continued.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Positive drug control	References
			Hot water (500–2000 µg/mL), ethanol (12.5–50 µg/mL), and ethyl acetate (25–100 µg/mL) extracts, cotreatment (6–24 hr)	(i) Inhibits NO and PGE ₂ production (ii) Inhibits iNOS and pro-IL-1β expression in LPS-stimulated macrophages	Gentisic acid (1 mM), cotreatment (18–24 hr)	[74]
			Methanol extract (100–200 µg/mL), pretreatment (30 min)	(i) Inhibits NO and PGE ₂ production (ii) Inhibits iNOS and COX-2 expression in LPS-induced macrophages	L-NAME (1–1.5 mM) and indomethacin (0.5–5 µM), pretreatment (30 min)	[75]
		<i>In vitro</i>	Water extract (0.01–0.5 mg/mL), cotreatment (12–18 hr)	(i) Inhibits PGE ₂ production in LPS-induced macrophages	NA	[76]
<i>Momordica charantia</i> (peria)	Cucurbitaceae		Ethanol, ethyl acetate, petroleum ether, and aqueous extracts (0.1 mg/mL), pretreatment (12 hr)	(i) Inhibits NO production in LPS-stimulated macrophages (i) Reduces serum levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and increases serum level of anti-inflammatory cytokine (IL-10)	Ibuprofen (0.1 mg/mL), pretreatment (12 hr)	[77]
		<i>In vivo</i>	Lyophilized powder (1%–10% (w/w)) in food pellets daily for 4 weeks before LPS challenge	(ii) Inhibits expression of NF-κB, iNOS, and COX-2 (iii) Diminishes liver injury biomarkers (ALT, AST, and C-RP) in LPS-induced mice	Pyridoline dithiocarbamic acid ammonium salt (PDTC) (50 mg/kg) via intravenous injection 1 hr before LPS challenge	[78]

TABLE 1: Continued.

Scientific name (local name)	Family	Experimental model	Type of sample (concentration or dose used)/mode and duration of treatment	Antisepsis properties	Antisepsis properties	Positive drug control	References
		<i>In vitro</i>	Ethanol extract (3.91–1000 µg/mL), posttreatment (24 hr)	(i) Inhibits NO, TNF- α , and PGE ₂ production in LPS-induced macrophages	(i) Inhibits NO, TNF- α , and PGE ₂ production in LPS-induced macrophages	Dexamethasone (5 µM), posttreatment (24 hr)	[79]
		<i>In vitro</i>	Asiatic acid (10–40 µM), cotreatment (48 hr)	(i) Inhibits NO, IL-1 β , and IL-6 production (ii) Inhibits NF- κ B activation in LPS-induced macrophages	(i) Inhibits NO, IL-1 β , and IL-6 production (ii) Inhibits NF- κ B activation in LPS-induced macrophages	NA	[80]
		<i>In vitro</i>	Ethanol extract (300 and 350 mg/kg) via oral administration after LPS challenge for 11 days	(i) Reduces serum levels of TNF- α and PGE ₂ in LPS-induced mice (i) Attenuates ALI (ii) Reduces serum levels of IL-6 and TNF- α (iii) Inhibits COX-2 and iNOS expression in lung tissue (iv) Inhibits NF- κ B activation in CLP-induced mice	(i) Reduces serum levels of TNF- α and PGE ₂ in LPS-induced mice (i) Attenuates ALI (ii) Reduces IL-6 and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	Rivastigmine (5 mg/kg) via oral administration after LPS challenge for 11 days	[79]
		<i>In vitro</i>	Asiaticoside (45 mg/kg) via intraperitoneal injection 1 hr before the CLP procedure	(i) Attenuates ALI (ii) Reduces IL-6 and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	(i) Attenuates ALI (ii) Reduces IL-6 and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	NA	[81]
		<i>In vitro</i>	Asiaticoside (15–45 mg/kg) via intraperitoneal injection 1 hr before LPS challenge	(i) Improves survival rate (ii) Attenuates liver injury (iii) Reduces serum levels of ALT and AST (iv) Decreases TNF- α level in serum and hepatic tissue in LPS-/D-galactosamine-induced mice	(i) Improves survival rate (ii) Attenuates liver injury (iii) Reduces serum levels of ALT and AST (iv) Decreases TNF- α level in serum and hepatic tissue in LPS-/D-galactosamine-induced mice	Silymarin (50 mg/kg) via oral administration for 3 days before LPS/D-galactosamine challenge	[82]
<i>Centella asiatica</i> (pegaga)	Apiaceae	<i>In vitro</i>	Asiaticoside (10 and 20 mg/kg) via oral administration for 3 days before the LPS/D-galactosamine challenge	(i) Reduces serum levels of IL-1 β , IL-6, and TNF- α (ii) Attenuates liver injury in LPS-treated rats (i) Attenuates ALI (ii) Reduces IL-1 β , IL-6, and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	(i) Reduces serum levels of IL-1 β , IL-6, and TNF- α (ii) Attenuates liver injury in LPS-treated rats (i) Attenuates ALI (ii) Reduces IL-1 β , IL-6, and TNF- α levels in BALF (iii) Inhibits NF- κ B activation in LPS-induced mice	Indomethacin (10 mg/kg) via oral administration at 24 hr before LPS challenge and every 8 hr thereafter	[84]
		<i>In vitro</i>	Asiatic acid (25–100 mg/kg) via intranasal administration 1 hr after LPS challenge	(i) Improves survival rate (ii) Attenuates organ (lung, liver, and kidney) damage (iii) Decreases serum levels of IL-1 β , IL-6, ALT, and BUN in LPS-induced mice (i) Prevents myocardial dysfunction (ii) Delays the drop in blood pressure (iii) Attenuates tachycardia in LPS-treated rats	(i) Improves survival rate (ii) Attenuates organ (lung, liver, and kidney) damage (iii) Decreases serum levels of IL-1 β , IL-6, ALT, and BUN in LPS-induced mice (i) Prevents myocardial dysfunction (ii) Delays the drop in blood pressure (iii) Attenuates tachycardia in LPS-treated rats	NA	[85]
		<i>In vitro</i>	Asiatic acid (10 and 30 mg/kg) via oral administration for 3 days before LPS challenge	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	NA	[80]
		<i>In vitro</i>	Madecassoside (20 mg/kg) via intragastric administration for 5 days before LPS challenge	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	NA	[86]
		<i>In vitro</i>	Madecassoside (20 and 40 mg/kg) via oral administration for 10 days before LPS challenge	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	(i) Prevents acute liver failure (ii) Reduces serum levels of ALT and AST (iii) Inhibits IL-1 β , IL-6, and TNF- α production in liver tissue (iv) Inhibits iNOS and COX-2 expression in LPS-/D-galactosamine-induced mice	Silibinin (100 mg/kg) via oral administration for 10 days before LPS challenge	[87]

dysfunction plays an important role in the pathogenesis of sepsis leading to multiple organ failure [88], and thus, therapeutic agents that effectively inhibit endothelial barrier dysfunction may have beneficial effect in sepsis. It should be noted that active constituents which only demonstrated *in vitro* pharmacological effects and lack supporting *in vivo* studies were not included in Table 1 but were briefly discussed under their respective herbal plants below. The anti-inflammatory effects of these active constituents as evidenced by the *in vitro* findings alone are not sufficient to support their antiseptis potential.

6. Malaysian Herbal Plants and Their Active Constituents with Potential Therapeutic Applications in Sepsis

6.1. *Andrographis paniculata*. *Andrographis paniculata* (*A. paniculata*), vernacularly known as King of Bitters, is a bushy medicinal plant distributed extensively in Southeast Asia and Southern Asia. In Malaysia, the plant is called “*hempedu bumi*” or “*pokok cerita*” and commonly found at the roadsides, on the hills, and in the forest bed. Traditionally, it has been used for cold, malaria, snake bites, diabetes, and hypertension [89]. Some of the effects of *A. paniculata* that have been scientifically proven include its antibacterial, antioxidant, antidiabetic, and anti-inflammatory effects [90–92].

The ethyl acetate extract of *A. paniculata* was previously found to have anti-inflammatory effects on LPS-/IFN- γ -induced macrophages and LPS-treated mice [43, 44]. An oral administration of the ethyl acetate extract (0.78–1.32 mg/kg) improved the survival rate of endotoxemic mice and reduced the serum levels of NO, TNF- α , and macrophage inflammatory protein (MIP)-2, all of which play proinflammatory roles in sepsis [44]. A bioassay-guided fractionation study revealed that eight bioactive compounds contributed to the inhibition of NF- κ B transcriptional activity of the ethyl acetate fraction, with the two most abundant compounds in the fraction being andrographolide and 14-deoxy-11,12-didehydroandrographolide [93]. In particular, andrographolide has been shown to exhibit barrier protective effect in HMGB-1-induced endothelial cells by decreasing permeability and monocytes adhesion and transmigration. Furthermore, andrographolide administered via intravenous injection was able to reduce sepsis-induced HMGB-1 production, inhibit vascular leakage, and improve the survival rate of CLP-treated mice [45]. Other studies have also reported similar *in vivo* protective effect where intraperitoneal injection of andrographolide attenuated acute lung injury (ALI) and acute liver injury in LPS-induced and LPS-/D-galactosamine-induced mice, respectively [46, 47]. Collectively, these findings suggest that andrographolide possesses strong antiseptis potential.

Apart from andrographolide, several studies have demonstrated that other bioactive compounds isolated from *A. paniculata* also possess anti-inflammatory activity. For example, isoandrographolide and neoandrographolide are two andrographolide derivatives which have been reported

to have the capability to inhibit the production of proinflammatory mediators, such as NO, PGE₂, IL-1 β , IL-6, and TNF- α , in LPS-induced macrophages [94–96]. Two other bioactive compounds, namely, skullcapflavone-1 and 7-O-methylwogonin, were also reported to exert *in vitro* inhibitory effect against LPS-induced NO and PGE₂ production in macrophages [96]. Besides that, andrograpanin which was reported by Liu et al. [97] to inhibit the production of inflammatory mediators in LPS-induced macrophages and other bioactive compounds which were reported by Chao et al. [93] to inhibit NF- κ B transcriptional activity are other active constituents from *A. paniculata* that should be further studied for their antiseptis potential.

6.2. *Zingiber officinale*. *Zingiber officinale* (*Z. officinale*), or ginger, belongs to the Zingiberaceae family. The ginger rhizome has a long history of medicinal use among Chinese and Indian community. It is now widely cultivated in various tropical countries, especially India. There are also wild varieties of this plant available in tropical and subtropical countries, including Malaysia. The health benefits of ginger are numerous, including antioxidant, anti-inflammatory, anticarcinogenic, and prevention of cardiovascular diseases [98–101].

The anti-inflammatory activity of ginger is supported by a study which reported that oral administration of dried ginger dissolved in distilled water was able to inhibit LPS-induced inflammation in a mouse model by suppressing the production of IL-6 and IFN- γ , mainly through the inhibition of NF- κ B signaling pathway [52]. Furthermore, the same study also demonstrated that the ginger extract could ameliorate liver damage, most likely due to its ability to reduce the expression of inflammatory enzymes (iNOS and COX-2) in the liver [52]. This is consistent with another study which reported that the inhibition of iNOS and COX-2 was able to abrogate liver injury [102]. These results suggest that the ginger extract may be beneficial not only as an anti-inflammatory agent but also to protect against tissue and organ damage commonly observed in severe sepsis cases.

An *in vitro* study by Tripathi et al. [48] demonstrated that the alcoholic extract of ginger suppressed LPS-induced activation of macrophages as indicated by decreased production of proinflammatory cytokines (IL-1 β , IL-12, and TNF- α) and chemokines (Regulated on Activation Normal T-Cells Expressed and Secreted (RANTES) and monocyte chemoattractant protein (MCP)-1). Another study also reported that the major constituent of *Z. officinale*—6-gingerol—exhibited similar inhibitory effects on LPS-stimulated macrophages [49], suggesting that the anti-inflammatory effects of the alcoholic extract of ginger reported previously [48] were largely attributed to 6-gingerol. Moreover, 6-gingerol was also shown to decrease the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two common biomarkers of liver injury, in CLP-induced polymicrobial sepsis [53]. Indeed, both its anti-inflammatory activity and its ability to suppress liver injury further highlight the antiseptis potential of 6-gingerol.

Other studies have also investigated the activity of zingerone, a phenolic alkanone found in *Z. officinale*, using *in vitro* and *in vivo* models. In particular, zingerone has been shown to inhibit the production of HMGB-1 and TGFBIp in LPS-induced human umbilical vein endothelial cells (HUVECs), as well as in CLP-induced septic mice [50, 51]. Both HMGB-1 and TGFBIp are proinflammatory mediators that promote vascular leakage in sepsis [19, 51]. Zingerone was able to inhibit HMGB-1- and TGFBIp-induced endothelial dysfunction through the suppression of hyperpermeability, cell adhesion molecules (CAMs) expression, and adhesion and transendothelial migration of neutrophils [50, 51]. Most importantly, zingerone's therapeutic effect is evidenced by its ability to decrease sepsis-related mortality and to reverse organ damage such as hepatic, renal, and pulmonary injury in CLP-induced septic mice at a dose of 0.72 mg/kg via intravenous injection [50]. Similar improvements in the survival rate and tissue damage were also observed in TGFBIp-induced CLP mice injected with zingerone (0.36 and 0.72 mg/kg) intravenously [51]. These findings are in line with other reports that described the ability of zingerone to alleviate lung and kidney injury in LPS-induced mice upon intragastric and intraperitoneal administration, respectively [54, 55]. These studies cumulatively suggest that *Z. officinale* or ginger has great therapeutic potential for sepsis by suppressing sepsis-related mediators and organ damage.

Other than 6-gingerol and zingerone, there are various active compounds isolated from ginger that have also shown great anti-inflammatory activity in LPS-induced macrophages, especially the shogaols, gingerols, and gingerdiones. Among the shogaols, 6-shogaol has been reported by a few *in vitro* studies to suppress LPS-induced inflammatory mediator production by inhibiting the expression of iNOS and COX-2 [103–105]. Moreover, 1-dehydro-10-gingerdione has also been shown to have similar inhibitory activity on iNOS expression, resulting in reduced production of NO [103]. Other gingerols (8- and 10-gingerol) and gingerdiones (1-dehydro-6-gingerdione and 12-dehydrogingerdione) are just a few among those that have been demonstrated to have *in vitro* anti-inflammatory activity [105–108] and may be further investigated *in vivo* for their potential therapeutic use for sepsis.

6.3. *Curcuma longa*. *Curcuma longa* (*C. longa*), usually known as turmeric, has been used for thousands of years in the Ayurvedic tradition as well as for culinary purpose. The plant, which belongs to the Zingiberaceae family, is a perennial herb known as “*kunyit*” in Malaysia. In folk medicine, *C. longa* is frequently used for the management of asthma, gonorrhoea, helminthic diseases, and urinary tract disorders [109]. Rhizome of *C. longa* is known to possess several therapeutic properties such as anti-inflammatory, antioxidant, antibacterial, antiviral, antifungal, and antidiabetic properties [110–114].

A previous study reported that oral administration of *C. longa* extract-loaded nanoemulsion (CLEN) was able to improve the survival rate of LPS-induced lethal endotoxemic mice [56], indicating the antiseptic potential of *C. longa*. The

protective effect of CLEN against endotoxin-induced mortality was associated with its ability to reduce serum levels of HMGB-1 and the expression of iNOS in various tissues including heart, lung, liver, and kidney [56].

Curcumin is a major compound found in the rhizome of *C. longa* and has been extensively studied for its antiseptic potential. Intravenous injection of curcumin rescued mice from CLP-induced lethality, lowered the levels of tissue injury markers, such as ALT, AST and lactate, and inhibited the production of TNF- α [57]. Intraperitoneal injection of curcumin also improved the survival rate and attenuated blood-brain barrier dysfunction in CLP-induced mice [58]. Apart from that, curcumin, administered via intranasal, intraperitoneal, and oral routes, exerted protective effects against organ dysfunction in LPS-induced endotoxemia, including acute lung injury and liver injury [59–61]. Notably, a more recent study by Kumari et al. [62] found that intraperitoneal, but not intranasal, administration increased the survival of LPS-induced mice and decreased TNF- α production. The failure of curcumin to yield reproducible results via intranasal administration suggests that it might not be an appropriate route of administration for curcumin because there are many factors that affect the bioavailability of intranasally administered drugs including their volume and concentration, and the absorptive surface of nasal mucosa [115] and thus an optimal formulation should be determined beforehand. Last but not least, curcumin also demonstrated beneficial effects on the cardiovascular system as intragastric injection of curcumin has been shown to prevent myocardial injury in CLP-induced septic mice [63], while intraperitoneal injection of curcumin has been shown to improve vascular function in LPS-challenged mice by maintaining a normal heart rate and blood pressure [64]. Based on these reports, it is evident that curcumin may prevent organ damage due to sepsis and thus have promising potential for the treatment of sepsis.

Some studies have also identified other active compounds from *C. longa* with anti-inflammatory activity. Some examples include turmeronol A and B, (6S)-2-methyl-5-hydroxy-6-(3-hydroxy-4-methylphenyl)-2-heptene-4-one, (6S)-2-methyl-6-(4-hydroxyphenyl)-2-heptene-4-one, and 4-methylene-5-hydroxybisabol-2,10-diene-9-one which have been shown to inhibit LPS-induced inflammatory responses *in vitro* [116, 117]. Further studies are required to determine whether these constituents may be the lead compound for further development to treat inflammatory diseases including sepsis. It is also worth noting that since curcumin is recognized as the most pharmacologically active constituent isolated from *C. longa*, many studies have also been conducted to improve the anti-inflammatory activity of curcumin through structural modifications [118–123].

6.4. *Piper nigrum*. *Piper nigrum* (*P. nigrum*), also widely known as black pepper, is one of the most commonly used spices for culinary purpose [124]. *P. nigrum* originated from India, and it is widely cultivated in Southeast Asia, especially Indonesia and Malaysia. In traditional Chinese medicine, *P. nigrum* has been used for the treatment of cold due to its

“warming” properties. On the contrary, *P. nigrum* plays an important role in Ayurvedic medicine as it can improve digestion and treat cold, cough, and fever [124]. Studies have also shown that it possesses antimicrobial, antioxidant, anticancer, and hepatoprotective properties [125–128].

A previous study demonstrated that the ethanol extract of *P. nigrum* was capable of down-regulating NO production in LPS-stimulated macrophages, indicating its inhibitory effect against LPS-mediated inflammatory responses [65]. Although evidence on the therapeutic potential of *P. nigrum* extract against sepsis is lacking, there are several studies that demonstrate the therapeutic potential of two of its active compounds, namely, piperine and peltitorine.

Piperine is the core constituent that gives black pepper its natural aromatic fragrance [129]. Piperine injection via intraperitoneal route improved the survival of mice with endotoxemia induced by LPS, as well as reduced serum levels of TNF- α [68]. Another study showed that intragastric administration of piperine reduced the secretion of IL-1 β in mice intraperitoneally infected with *Escherichia coli*, suggesting its ability to suppress systemic inflammation caused by bacteria [66]. This finding is consistent with results from an *in vitro* study, whereby piperine also suppressed the release of IL-1 β and HMGB-1 by LPS-stimulated macrophages [66]. Additionally, intraperitoneal injection of piperine also attenuated LPS-induced ALI in mice, most probably due to the reduced production of proinflammatory cytokines such as IL-1 β , IL-6, and TNF- α [69].

Peltitorine is another compound in *P. nigrum* that has garnered much research attention. This compound has been shown to be effective against sepsis in both *in vitro* and *in vivo* models. Peltitorine demonstrated excellent protective effects against vascular barrier dysfunction by reducing permeability, CAMs expression, and leukocytes transmigration in HMGB-1-induced HUVECs and mice [67]. Most importantly, an intravenous dose of peltitorine as low as 9 μ g/mouse reduced the mortality of septic mice [67]. However, these evidences suggest that *P. nigrum* may possess antiseptic effect.

Besides piperine and peltitorine, a few studies have also identified other active compounds isolated from *P. nigrum*. Although some of these compounds showed more potent anti-inflammatory activity *in vitro*, their activity in sepsis animal models has not yet been reported. For example, Ngo et al. [130] reported that there are five alkaloids including peltitorine that significantly inhibited NO production in LPS-induced macrophages but chabamide was the most potent among them. Another study reported that some new amide alkaloids isolated from the ethanol extract of *P. nigrum* significantly inhibited LPS-induced NO, IL-1 β , IL-6, and TNF- α production by macrophages [131]. Amongst the isolated amide alkaloids, pipernigramides E-G were shown to exert anti-inflammatory activity in the carrageenan-induced paw edema test [131].

6.5. *Syzygium aromaticum/Eugenia caryophyllata*. *Syzygium aromaticum* (*S. aromaticum*) (synonym: *Eugenia caryophyllata*), commonly called cloves, has been used as a

spice for centuries as it exudes a distinct aroma due to the presence of its constituent—eugenol. Cloves specifically refer to the nail-shaped dried flower buds from the *S. aromaticum* plant, which originated from east Indonesia [132]. The medicinal properties of cloves include antimicrobial, antinociceptive, antioxidant, and anti-inflammatory effects [133–135].

Although *S. aromaticum* flower buds aqueous extract has been shown to inhibit LPS-induced lung inflammation *in vivo* [73], neither the extract nor the compound isolated from it has been extensively studied for antiseptic properties. Different extracts (acetone, ethanol, and methanol extracts) of *S. aromaticum* flower buds demonstrated antibacterial activity against neonatal sepsis-causing bacteria such as *E. coli*, *Staphylococcus aureus*, *Enterococcus* sp., *Klebsiella* sp., and *Pseudomonas* sp., with the most effective being methanol extract which gave the lowest minimum inhibitory concentration (MIC) [136]. However, this result should be interpreted with caution in terms of its antiseptic potential in general as infections by many other organisms could also lead to sepsis or septic shock. The anti-inflammatory activity of *S. aromaticum* is supported by several studies. For example, the methanol extract of *S. aromaticum* has been shown to inhibit the production of IL-1 β , IL-6, IL-10, and PGE₂ in LPS-induced macrophages [70, 71]. Bachiega et al. [71] also demonstrated that eugenol inhibited the production of IL-6 and IL-10 but had no effect on IL-1 β . Besides eugenol, another compound isolated from the flower buds of *S. aromaticum* called biflorin suppressed LPS-stimulated release of inflammatory mediators such as NO, PGE₂, TNF- α , and IL-6 by macrophages. In the same study, biflorin also improved the survival rate of LPS-induced endotoxemic mice [72]. Overall, the evidence on the antiseptic effect of *S. aromaticum* is still limited, and more extensive studies are required in the future.

6.6. *Momordica charantia*. Bitter gourd, or bitter melon, scientifically known as *Momordica charantia* (*M. charantia*), is a well-known vegetable for its bitter taste. The plant is natively found in Asia, Africa, Amazon, and the Caribbean and is now widely cultivated in China and India for commercial purposes. Bitter gourd is valuable as a traditional herbal remedy with proven anti-inflammatory, antioxidant, anticarcinogenic, antimicrobial, and antidiabetic properties [137–140]. After several years of research, *M. charantia* is believed to be one of the most promising natural therapies that could be used to treat diabetes mellitus—a disease that affects numerous people all around the world [141].

Although it is more renowned for its hypoglycemic effect to treat diabetes, increasing evidence supports the antiseptic potential of bitter gourd. An *in vivo* study involving an LPS-stimulated mouse model of sepsis reported reduced levels of inflammatory mediators (TNF- α , IL-1 β , and IL-6) and an elevated level of the anti-inflammatory cytokine IL-10 in septic mice fed with lyophilized powder of wild bitter gourd-supplemented diet [78]. These anti-inflammatory effects correlated with reduced levels of ALT, AST, and C-RP, all of which are markers of liver injury, suggesting its

hepatoprotective effect [78]. Several *in vitro* studies have also demonstrated the anti-inflammatory activity of bitter melon. For example, an *in vitro* study reported that wild bitter melon fruit extracts (hot water, ethanol, and ethyl acetate extracts) were effective against LPS-induced inflammatory responses in macrophages, mainly by attenuating the secretion of NO and PGE₂ and the expression of iNOS and pro-IL-1 β [74]. Its inhibitory effect on NO and PGE₂ is further supported by other studies which reported similar findings using different extracts of bitter melon on LPS-stimulated macrophages [75–77]. Together, these findings highlight its potential to prevent the inflammatory response and ensuing organ damage in sepsis.

The active constituent(s) responsible for the antiseptic effects of bitter melon remains unknown; however, numerous active compounds isolated from *M. charantia* have recently been shown to have *in vitro* anti-inflammatory activity. Notably, seven compounds isolated from the acetone and methanol extracts of bitter melon inhibited LPS-induced inflammatory responses in macrophages and gentisic acid, 5-O- β -D-xyloside, which was isolated for the first time from bitter melon, has been shown to inhibit the expression of COX-2 and IL-6 [142]. In another study by Shivanagoudra et al. [143], charantoside XI exhibited the most significant anti-inflammatory activity on LPS-induced macrophages compared to the other three cucurbitane-type compounds. The antiseptic potential of these active compounds remains to be explored in future studies.

6.7. *Centella asiatica*. In Malaysia, *Centella asiatica* (*C. asiatica*) is commonly known as “pegaga” [144]. *C. asiatica* has been traditionally used, especially in India and China, for medicinal purposes including for wound healing, stimulation of neurons, and to treat skin diseases [145]. Numerous pharmacological activities of the plant have been reviewed, including wound healing, antitumor, memory enhancing, antioxidant, anti-inflammatory, and protective effects on the liver, heart, and brain [146].

C. asiatica ethanol extract has been shown to have prominent anti-inflammatory effects both *in vitro* and *in vivo*, as indicated by its inhibition of TNF- α and PGE₂ production in LPS-induced macrophages and LPS-induced mice, respectively [79]. While there is limited evidence on the antiseptic potential of *C. asiatica* extract, a few compounds isolated from the plant, namely, asiaticoside, asiatic acid, and madecassoside, have shown antiseptic activities. Intraperitoneal injection of asiaticoside, a triterpenoid saponin, in CLP-induced mice, reduced the serum levels of IL-6 and TNF- α , the expression of COX-2 and iNOS in lung tissue, and the severity of lung injury due to sepsis [81]. Importantly, asiaticoside treatment also improved the survival of CLP-induced mice [81]. In a mouse model of LPS-induced ALI, asiaticoside demonstrated similar beneficial effects by decreasing the degree of lung damage [82]. Asiaticoside has also been reported to attenuate liver injury in LPS-/D-galactosamine-induced mice and LPS-induced rats [83, 84]. Asiatic acid is a major triterpene isolated from *C. asiatica*. Injection of asiatic acid via the intranasal route

attenuated ALI via downregulation of TLR4 expression, suppression of NF- κ B activation, and subsequent inhibition of proinflammatory cytokines (IL-1 β , IL-6, and TNF- α) production in LPS-induced mice [85]. Besides that, a more recent study found that the oral administration of asiatic acid resulted in increased survival rate and reduced organ damage in LPS-induced endotoxemic mice [80]. Madecassoside, another major triterpenoid, has also been associated with tissue protective effects *in vivo*. An intragastric injection of madecassoside has been shown to have cardioprotective effects against myocardial dysfunction in LPS-treated rats by reducing plasma TNF- α , preventing the fall in blood pressure and attenuating the severity of tachycardia [86]. Furthermore, an oral administration of madecassoside was able to prevent acute liver failure in LPS-/D-galactosamine-induced mice [87].

Two other triterpenoids, namely, madecassic acid and asiaticoside G, have been shown to have anti-inflammatory effect *in vitro*. Won et al. [147] reported that madecassic acid had a stronger inhibitory effect on the production of NO, PGE₂, TNF- α , IL-1 β , and IL-6 in LPS-induced macrophages compared to madecassoside. In addition, asiaticoside G, a new ursane-type triterpenoid glycoside isolated from *C. asiatica* leaves, has been shown to have stronger inhibitory effect against LPS-induced NO and TNF- α production in macrophages compared to asiaticoside and asiatic acid [148]. Thus, it would be interesting to further investigate whether these two compounds have therapeutic effects in sepsis animal models (see Figure 1).

7. Discussion

Sepsis is a major cause of death and morbidity worldwide [8, 12]. The current approaches in managing sepsis patients include initial resuscitation, early diagnosis to allow prompt treatment using specific antibiotics, and identification of infection source and control measures [2]. These have improved the outcomes of sepsis patients; however, the mortality rate remains unreasonably high [4]. Furthermore, the reliance on antibiotics may exacerbate the global threat of multidrug-resistant organisms, leaving no treatment option for sepsis [149]. An alternative approach—a specific antiseptic treatment, is urgently needed to ease the global burden of sepsis due to the tremendous costs incurred in the management of patients [8]. Hence, this review aims to give some insights into Malaysian herbal plants and their active constituents which have the potential to be further developed into alternative treatments for sepsis.

Among the herbal plants discussed in this review, *Z. officinale* and *A. paniculata* are natively found in Malaysia, whilst others are naturalized species since years ago. Based on the literature, *Z. officinale*, or ginger, seems to show the highest potential to be developed for therapeutic use in sepsis. This is evidenced by promising results from different experimental models, both *in vitro* and *in vivo*, which involved different forms of ginger—alcoholic extract of ginger, dried ginger water extract, 6-gingerol, and zingerone [48–55]. The greatest effect was demonstrated by zingerone, a phenolic alkanone isolated from ginger.



FIGURE 1: Photos of Malaysian herbal plants with therapeutic potential for sepsis: (a) whole plant of *Andrographis paniculata*; (b) rhizome of *Zingiber officinale*; (c) rhizome of *Curcuma longa*; (d) *Piper nigrum* berries; (e) dried flower buds of *Syzygium aromaticum*; (f) fruits of *Momordica charantia*; and (g) whole plant of *Centella asiatica*. GLOBinMED, https://www.globinmed.com/index.php?option=com_content&view=category&id=209&Itemid=143 (accessed 4 March 2020).

Zingerone was able to enhance the survival rate and attenuate injury in organs commonly affected by sepsis, which are the kidney, liver, and lung, at a low dose of 0.72 mg/kg in CLP-induced mice [50, 51]. Furthermore, there is an ongoing clinical trial in China that evaluates the efficacy of “*Si-Ni-Tang*,” a traditional Chinese medicine formulation comprising of ginger, in treating sepsis [150]. This further supports the potential use of ginger for sepsis. Other than *Z. officinale*, this traditional remedy is composed of processed *Glycyrrhiza uralensis* and *Aconitum carmichaeli*, based on the rationale that the simultaneous use of herbal plants with different pharmacological activities is likely to be more effective as a treatment for septic shock patients [150]. This is also one of the traditional remedies used to treat sepsis or septic shock as documented in the ancient medical collection called “*Shanghan Lun*” [150].

For some herbal plants, evidence on their antiseptic potential is largely demonstrated by specific constituents or compounds isolated from the plant extracts. For instance, andrographolide is a major constituent in the ethyl acetate fraction of *A. paniculata* [93] and is thought to largely

contribute to the antiseptic effect of *A. paniculata* ethyl acetate extract in LPS-induced endotoxemia [44]. Andrographolide at a dose of 1 to 10 mg/kg via intraperitoneal injection was demonstrated to attenuate acute lung injury and acute liver injury in LPS-induced and LPS-/D-galactosamine-induced mice, respectively [46, 47], whereas a relatively lower dose (3.5 to 7 μ g/mouse) via intravenous injection enhanced the survival of CLP-induced mice [45]. For *C. longa*, curcumin is the major constituent and it has been shown to promote survival and exert organ-protective effects against sepsis-induced injury in numerous studies [56–64, 106–114]. It is likely that the antiseptic effect of *C. longa*, as indicated by the enhanced survival rate of LPS-induced mice receiving CLEN treatment [56], is attributed to curcumin. Both andrographolide and curcumin are the most pharmacologically active constituent and the most widely studied phytochemical in their respective plants [89, 151].

In comparison to *A. paniculata* and *C. longa*, more than one active constituent with antiseptic potential has been identified from *P. nigrum* and *C. asiatica*. Specifically, these constituents are piperine and pellitorine from *P. nigrum* and

asiaticoside and asiatic acid and madecassoside from *C. asiatica*. Piperine was demonstrated to be effective in inhibiting the systemic inflammatory responses induced by LPS as well as *E. coli* [66, 68, 69], whereas pellitorine is more likely to be an active compound that protects the endothelial barrier as it has been shown to inhibit vascular endothelial dysfunction, both *in vitro* and *in vivo* [67]. Piperine and pellitorine can also be found in the other member within the same genus such as *P. longum*, which is commonly known as long pepper [152]. Asiaticoside, asiatic acid, and madecassoside, on the contrary, were demonstrated to protect against organ dysfunction [80–87]. These three active principles, together with madecassic acid, are triterpenes that are believed to be the major components that contribute to the medicinal value of *C. asiatica* [144]. Notably, these active constituents were all given within a similar dose range (1 to 100 mg/kg) via different routes (oral, intragastric, intraperitoneal, and intranasal), except pellitorine which was injected intravenously at a substantially lower dose of 4.5 to 9.0 $\mu\text{g}/\text{mouse}$ [67]. This finding indicates that the active compounds may be required at a relatively lower dose to achieve the desired therapeutic effects if they are administered intravenously compared to the other routes.

Among the plants discussed in this review, there are relatively fewer studies on *S. aromaticum* and *M. charantia*. The aqueous extract of *S. aromaticum* flower buds has been shown to inhibit lung inflammation in LPS-induced mice [73], but the active constituent responsible for the anti-inflammatory activity *in vivo* remains unknown. Biflorin, an active compound isolated from the butanol-soluble fraction of the ethanol extract of *S. aromaticum* flower buds, however, has been shown to improve the survival rate of LPS-induced endotoxemic mice [72]. Thus, it is likely that there is other active constituent present in the flower buds of *S. aromaticum* that may also have antiseptic potential. Unlike the other active constituents mentioned, biflorin was originally isolated from *Capraria biflora*, a perennial shrub distributed in North and South America [153]. In contrast to the other plants, *M. charantia* has the least evidence to support its antiseptic potential. In particular, the lyophilized powder of *M. charantia*, given in the form of supplemented food pellets, has been shown to have *in vivo* anti-inflammatory and hepatoprotective effects in LPS-induced mice [81]. Although this may imply that *M. charantia* may treat sepsis by suppressing the inflammatory response and associated liver damage, further studies using different models of sepsis are required. Furthermore, the active compound responsible for the therapeutic effects is yet to be identified.

In summary, the active constituents which are predominantly found in the Malaysian herbal plants have shown great antiseptic effects in the preclinical studies and should be further evaluated for their therapeutic potential against sepsis in the clinical settings.

8. Conclusion

The lack of a cure for sepsis and the sole dependence on antibiotics for sepsis management highlight the need to consider alternative treatments for sepsis. Some herbal

plants available in Malaysia, particularly their active constituents, have shown promising antiseptic potential and are worth to be tested clinically in order to find an effective treatment for sepsis.

Data Availability

The data used to support the findings in the study are available on reasonable request to the corresponding author.

Disclosure

The funding sources had no further role in the study design, collection, analysis, and interpretation of data, the writing of the report, or in the decision to submit the paper for publication.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to acknowledge Miss Audrey Siew Foong Kow for her kind contribution in proofreading the manuscript. This work was supported by the Fundamental Research Grant Scheme (FRGS) 2013 from Ministry of Higher Education Malaysia (FRGS/1/2012/SKK03/UPM/02/1) and Putra Grant—Putra Graduate Initiative 2014 from Universiti Putra Malaysia (GP-IPS/2014/9433948).

Supplementary Materials

The list of 64 Malaysian herbal plants documented in the Malaysian Herbal Monograph 2015 is provided in the Supplementary Material (Table A). (*Supplementary Materials*)

References

- [1] K. Reinhart, R. Daniels, N. Kissoon, F. R. Machado, R. D. Schachter, and S. Finfer, "Recognizing sepsis as a global health priority—a WHO resolution," *New England Journal of Medicine*, vol. 377, no. 5, pp. 414–417, 2017.
- [2] A. Rhodes, L. E. Evans, W. Alhazzani et al., "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016," *Intensive Care Medicine*, vol. 43, no. 3, pp. 304–377, 2017.
- [3] P. A. Ward, "New approaches to the study of sepsis," *EMBO Molecular Medicine*, vol. 4, no. 12, pp. 1234–1243, 2012.
- [4] M. Singer, C. S. Deutschman, C. W. Seymour et al., "The third international consensus definitions for sepsis and septic shock (sepsis-3)," *JAMA*, vol. 315, no. 8, pp. 801–810, 2016.
- [5] X.-h. Levy, Y. J. Yin, and J. X. Zhang, "Sepsis and immune response," *World Journal of Emergency Medicine*, vol. 2, no. 2, p. 88, 2011.
- [6] T. H. Mogensen, "Pathogen recognition and inflammatory signaling in innate immune defenses," *Clinical Microbiology Reviews*, vol. 22, no. 2, pp. 240–273, 2009.
- [7] W. Schulte, J. Bernhagen, and R. Bucala, "Cytokines in sepsis: potent immunoregulators and potential therapeutic

- targets—an updated view,” *Mediators of Inflammation*, vol. 2013, 2013.
- [8] S. Dugani, J. Veillard, and N. Kissoon, “Reducing the global burden of sepsis,” *Canadian Medical Association Journal*, vol. 189, no. 1, pp. E2–E3, 2017.
 - [9] C. Fleischmann, A. Scherag, N. K. J. Adhikari et al., “Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations,” *American Journal of Respiratory and Critical Care Medicine*, vol. 193, no. 3, pp. 259–272, 2016.
 - [10] R. B. Dantes and L. Epstein, “Combatting sepsis: a public health perspective,” *Clinical Infectious Diseases*, vol. 67, no. 8, pp. 1300–1302, 2018.
 - [11] C. Rhee, R. Dantes, L. Epstein et al., “and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014,” *Jama*, vol. 318, no. 13, pp. 1241–1249, 2017.
 - [12] J. M. Martin, L. Tai, C. Tan, S. Ahmad, and C. Lim, “Malaysian registry of intensive care report 2017,” November 2019, <http://www.mric.org.my/Content/Document/MRICPublications/mricreport2010.pdf>.
 - [13] F. Hashairi, H. Hasan, K. Azlan, and Z. Z. Deris, “An eight-year review of blood culture and susceptibility among sepsis cases in an emergency department in Northeastern Malaysia,” *Tropical Biomedicine*, vol. 28, no. 3, pp. 599–605, 2011.
 - [14] J. Cohen, “The immunopathogenesis of sepsis,” *Nature*, vol. 420, no. 6917, pp. 885–891, 2002.
 - [15] W. J. Wiersinga, S. J. Leopold, D. R. Cranendonk, and T. van der Poll, “Host innate immune responses to sepsis,” *Virulence*, vol. 5, no. 1, pp. 36–44, 2014.
 - [16] J. A. Russell, J. Boyd, T. Nakada, S. Thair, and K. R. Walley, “Molecular mechanisms of sepsis,” *Sepsis - Pro-Inflammatory and Anti-Inflammatory Responses*, vol. 17, pp. 48–85, 2011.
 - [17] B. Gyawali, K. Ramakrishna, and A. S. Dharmoon, “Sepsis: the evolution in definition, pathophysiology, and management,” *SAGE Open Medicine*, vol. 7, 2019.
 - [18] D. Rittirsch, M. A. Flierl, and P. A. Ward, “Harmful molecular mechanisms in sepsis,” *Nature Reviews Immunology*, vol. 8, no. 10, pp. 776–787, 2008.
 - [19] W. Huang, Y. Tang, and L. Li, “HMGB1, a potent proinflammatory cytokine in sepsis,” *Cytokine*, vol. 51, no. 2, pp. 119–126, 2010.
 - [20] M. P. Fink, “Prostaglandins and sepsis: still a fascinating topic despite almost 40 years of research,” *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 281, no. 3, pp. L534–L536, 2001.
 - [21] D. M. Aronoff, “Cyclooxygenase inhibition in sepsis: is there life after death?” *Mediators of Inflammation*, vol. 2012, 2012.
 - [22] L. Wang, J. Wu, X. Guo, X. Huang, and Q. Huang, “RAGE plays a role in LPS-induced NF- κ B activation and endothelial hyperpermeability,” *Sensors*, vol. 17, no. 4, p. 722, 2017.
 - [23] K. Peters, R. E. Unger, J. Brunner, and C. J. Kirkpatrick, “Molecular basis of endothelial dysfunction in sepsis,” *Cardiovascular Research*, vol. 60, no. 1, pp. 49–57, 2003.
 - [24] R. P. Dellinger, J. M. Carlet, H. Masur et al., “Sepsis Campaign guidelines for management of severe sepsis and septic shock,” *Intensive Care Medicine*, vol. 30, no. 4, pp. 536–555, 2004.
 - [25] R. P. Zimmerman, M. M. Levy, J. M. Carlet et al., “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008,” *Intensive Care Medicine*, vol. 34, no. 1, pp. 17–60, 2008.
 - [26] S. S. Dhainaut, R. P. Dellinger, M. M. Levy et al., “International guidelines for management of severe sepsis and septic shock,” *Critical Care Medicine*, vol. 41, no. 2, pp. 580–637, 2013.
 - [27] M. M. Levy, L. E. Evans, and A. Rhodes, “The surviving sepsis campaign bundle: 2018 update,” *Intensive Care Medicine*, vol. 44, no. 6, pp. 925–928, 2018.
 - [28] R. Herrán-Monge, A. Muriel-Bombín, M. M. García-García et al., “Mortality reduction and long-term compliance with surviving sepsis campaign,” *Shock*, vol. 45, no. 6, pp. 598–606, 2016.
 - [29] E. Fernández Calavia, R. Wunderink, H. Silverman et al., “Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group,” *JAMA: The Journal of the American Medical Association*, vol. 273, no. 12, pp. 934–941, 1995.
 - [30] E. Abraham, M. P. Glauser, T. Butler et al., “p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group,” *JAMA: The Journal of the American Medical Association*, vol. 277, no. 19, pp. 1531–1538, 1997.
 - [31] C. J. Fisher, J. F. Dhainaut, S. M. Opal et al., “Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. phase III rhIL-1ra sepsis syndrome study group,” *JAMA: The Journal of the American Medical Association*, vol. 271, no. 23, pp. 1836–1843, 1994.
 - [32] B. D. Freeman, B. A. Zehnbauser, and T. G. Buchman, “A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis,” *Shock*, vol. 20, no. 1, pp. 5–9, 2003.
 - [33] A. López, J. A. Lorente, J. Steingrub et al., “Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock,” *Critical Care Medicine*, vol. 32, no. 1, pp. 21–30, 2004.
 - [34] A. M. Takala, “Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsis,” *Baylor University Medical Center Proceedings*, vol. 15, no. 2, pp. 224–227, 2002.
 - [35] R. S. Green, D. Djogovic, and D. Howes, “Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris,” *CJEM*, vol. 14, no. 5, pp. 265–266, 2011.
 - [36] B. Rochweg, S. J. Oczkowski, R. A. C. Siemieniuk et al., “Corticosteroids in sepsis,” *Critical Care Medicine*, vol. 46, no. 9, pp. 1411–1420, 2018.
 - [37] K. Menon, “Sepsis treatment options are often lacking,” *P & T: A Peer-Reviewed Journal for Formulary Management*, vol. 40, no. 7, p. 466, 2015.
 - [38] J. A. Buras, B. Holzmann, and M. Sitkovsky, “Animal models of sepsis: setting the stage,” *Nature Reviews Drug Discovery*, vol. 4, no. 10, pp. 854–865, 2005.
 - [39] L. F. Poli-de-Figueiredo, A. G. Garrido, N. Nakagawa, and P. Sannomiya, “Experimental models of sepsis and their clinical relevance,” *Shock*, vol. 30, no. 7, pp. 53–59, 2008.
 - [40] L. Dejager, I. Pinheiro, E. Dejonckheere, and C. Libert, “Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?” *Trends in Microbiology*, vol. 19, no. 4, pp. 198–208, 2011.
 - [41] X.-Z. Su and L. H. Miller, “The discovery of artemisinin and the Nobel prize in Physiology or medicine,” *Science China Life Sciences*, vol. 58, no. 11, pp. 1175–1179, 2015.
 - [42] L. Kim Sooi and S. Lean Keng, “Herbal medicines: Malaysian women’s knowledge and practice,” *Evidence-Based*

- Complementary and Alternative Medicine*, vol. 2013, Article ID 438139, 10 pages, 2013.
- [43] W.-W. Chao, Y.-H. Kuo, W.-C. Li, and B.-F. Lin, "The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by *Andrographis paniculata*, *Angelica sinensis* and *Morus alba* ethyl acetate fractions," *Journal of Ethnopharmacology*, vol. 122, no. 1, pp. 68–75, 2009.
- [44] W. W. Chao, Y. H. Kuo, S. L. Hsieh, and B. F. Lin, "Inhibitory effects of ethyl acetate extract of *Andrographis paniculata* on NF- κ B trans-activation activity and LPS-induced acute inflammation in mice," *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 254531, 9 pages, 2011.
- [45] W. Lee, S. Ku, H. Yoo, K. Song, and J. Bae, "Andrographolide inhibits HMGB1-induced inflammatory responses in human umbilical vein endothelial cells and in murine polymicrobial sepsis," *Acta Physiologica*, vol. 211, no. 1, pp. 176–187, 2014.
- [46] T. Zhu, D. X. Wang, W. Zhang et al., "Andrographolide protects against LPS-induced acute lung injury by inactivation of NF- κ B," *PLoS One*, vol. 8, no. 2, 2013.
- [47] C.-W. Pan, S.-X. Yang, Z.-Z. Pan et al., "Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway," *Oncotarget*, vol. 8, no. 25, p. 41202, 2017.
- [48] S. Tripathi, D. Bruch, and D. S. Kittur, "Ginger extract inhibits LPS induced macrophage activation and function," *BMC Complementary and Alternative Medicine*, vol. 8, no. 1, p. 1, 2008.
- [49] S. Tripathi, K. G. Maier, D. Bruch, and D. S. Kittur, "Effect of 6-gingerol on pro-inflammatory cytokine production and costimulatory molecule expression in murine peritoneal macrophages," *Journal of Surgical Research*, vol. 138, no. 2, pp. 209–213, 2007.
- [50] W. Lee, S.-K. Ku, and J.-S. Bae, "Zingerone reduces HMGB1-mediated septic responses and improves survival in septic mice," *Toxicology and Applied Pharmacology*, vol. 329, pp. 202–211, 2017.
- [51] G. Min, S.-K. Ku, T. Lee, and J.-S. Bae, "Suppressive effects of zingerone on TGF β 1p-mediated septic responses," *Archives of Pharmacol Research*, vol. 41, no. 3, pp. 276–287, 2018.
- [52] Y. Y. Choi, M. H. Kim, J. Hong, S. H. Kim, and W. M. Yang, "Dried ginger (*Zingiber officinalis*) inhibits inflammation in a lipopolysaccharide-induced mouse model," *Evidence-based Complementary and Alternative Medicine*, vol. 2013, 2013.
- [53] M.-K. Hong, L.-L. Hu, Y.-X. Zhang et al., "6-Gingerol ameliorates sepsis-induced liver injury through the Nrf2 pathway," *International Immunopharmacology*, vol. 80, p. 106196, 2020.
- [54] X. Xie, S. Sun, W. Zhong et al., "Zingerone attenuates lipopolysaccharide-induced acute lung injury in mice," *International Immunopharmacology*, vol. 19, no. 1, pp. 103–109, 2014.
- [55] J. Song, H.-J. Fan, H. Li, H. Ding, Q. Lv, and S.-K. Hou, "Zingerone ameliorates lipopolysaccharide-induced acute kidney injury by inhibiting Toll-like receptor 4 signaling pathway," *European Journal of Pharmacology*, vol. 772, pp. 108–114, 2016.
- [56] M. Y. Ahn, J. S. Hwang, S. B. Lee et al., "Curcumin longa extract-loaded nanoemulsion improves the survival of endotoxemic mice by inhibiting nitric oxide-dependent HMGB1 release," *PeerJ*, vol. 5, p. e3808, 2017.
- [57] A. M. Siddiqui, X. Cui, R. Wu et al., "The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor- γ ," *Critical Care Medicine*, vol. 34, no. 7, pp. 1874–1882, 2006.
- [58] V. Vachharajani, S. W. Wang, N. Mishra, M. El Gazzar, B. Yoza, and C. McCall, "Curcumin modulates leukocyte and platelet adhesion in murine sepsis," *Microcirculation*, vol. 17, no. 6, pp. 407–416, 2010.
- [59] A. Kumari, N. Tyagi, D. Dash, and R. Singh, "Intranasal curcumin ameliorates lipopolysaccharide-induced acute lung injury in mice," *Inflammation*, vol. 38, no. 3, pp. 1103–1112, 2015.
- [60] J. Kim, S.-W. Jeong, H. Quan, C.-W. Jeong, J.-I. Choi, and H.-B. Bae, "Effect of curcumin (*Curcuma longa* extract) on LPS-induced acute lung injury is mediated by the activation of AMPK," *Journal of Anesthesia*, vol. 30, no. 1, pp. 100–108, 2016.
- [61] W. Zhong, K. Qian, J. Xiong, K. Ma, A. Wang, and Y. Zou, "Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppression of oxidative stress-related inflammation via PI3K/AKT and NF- κ B related signaling," *Biomedicine & Pharmacotherapy*, vol. 83, pp. 302–313, 2016.
- [62] A. Kumari, D. Dash, and R. Singh, "Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF- α and TGF- β 1) in murine model," *Inflammopharmacology*, vol. 25, no. 3, pp. 329–341, 2017.
- [63] C. Yang, K. Wu, S.-H. Li, and Q. You, "Protective effect of curcumin against cardiac dysfunction in sepsis rats," *Pharmaceutical Biology*, vol. 51, no. 4, pp. 482–487, 2013.
- [64] K. Sompamit, U. Kukongviriyapan, S. Nakmareong, P. Pannangpetch, and V. Kukongviriyapan, "Curcumin improves vascular function and alleviates oxidative stress in non-lethal lipopolysaccharide-induced endotoxaemia in mice," *European Journal of Pharmacology*, vol. 616, no. 1–3, pp. 192–199, 2009.
- [65] A. Anuthakoengkun and A. Itharat, "Inhibitory effect on nitric oxide production and free radical scavenging activity of Thai medicinal plants in osteoarthritic knee treatment," *Journal of the Medical Association of Thailand*, vol. 97, pp. S116–S124, 2014.
- [66] Y. D. Liang, W. J. Bai, C. G. Li et al., "Piperine suppresses pyroptosis and interleukin-1 β release upon ATP triggering and bacterial infection," *Frontiers in Pharmacology*, vol. 7, p. 390, 2016.
- [67] S.-K. Ku, I.-C. Lee, J. A. Kim, and J.-S. Bae, "Anti-septic effects of pellitorine in HMGB1-induced inflammatory responses *in vitro* and *in vivo*," *Inflammation*, vol. 37, no. 2, pp. 338–348, 2014.
- [68] G. S. Bae, M. S. Kim, W. S. Jung et al., "Inhibition of lipopolysaccharide-induced inflammatory responses by piperine," *European Journal of Pharmacology*, vol. 642, no. 1–3, pp. 154–162, 2010.
- [69] Y. Lu, J. Liu, H. Li, and L. Gu, "Piperine ameliorates lipopolysaccharide-induced acute lung injury via modulating NF- κ B signaling pathways," *Inflammation*, vol. 39, no. 1, pp. 303–308, 2016.
- [70] S. S. Kim, O.-J. Oh, H.-Y. Min et al., "Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells," *Life Sciences*, vol. 73, no. 3, pp. 337–348, 2003.
- [71] T. F. Bachiega, J. P. B. de Sousa, J. K. Bastos, and J. M. Sforcin, "Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine

- production by murine macrophages," *Journal of Pharmacy and Pharmacology*, vol. 64, no. 4, pp. 610–616, 2012.
- [72] H.-H. Lee, J.-S. Shin, W.-S. Lee, B. Ryu, D. S. Jang, and K.-T. Lee, "Biflorin, isolated from the flower buds of *Syzygium aromaticum* L., suppresses LPS-induced inflammatory mediators via STAT1 inactivation in macrophages and protects mice from endotoxin shock," *Journal of Natural Products*, vol. 79, no. 4, pp. 711–720, 2016.
- [73] A. Chniguir, F. Zioud, V. Marzaoli, J. El-Benna, and R. Bachoual, "Syzygium aromaticum aqueous extract inhibits human neutrophils myeloperoxidase and protects mice from LPS-induced lung inflammation," *Pharmaceutical Biology*, vol. 57, no. 1, pp. 55–63, 2019.
- [74] C.-K. Lii, H.-W. Chen, W.-T. Yun, and K.-L. Liu, "Suppressive effects of wild bitter gourd (*Momordica charantia* Linn. var. *abbreviata* ser.) fruit extracts on inflammatory responses in RAW 264.7 macrophages," *Journal of Ethnopharmacology*, vol. 122, no. 2, pp. 227–233, 2009.
- [75] W. S. Yang, E. Yang, M.-J. Kim et al., "Momordica charantia inhibits inflammatory responses in murine macrophages via suppression of TAK1," *The American Journal of Chinese Medicine*, vol. 46, no. 02, pp. 435–452, 2018.
- [76] C.-j. Huang and M.-C. Wu, "Differential effects of foods traditionally regarded as 'heating' and 'cooling' on prostaglandin E2 production by a macrophage cell line," *Journal of Biomedical Science*, vol. 9, no. 6, pp. 596–606, 2002.
- [77] T. M. H. Pham, D.-H. Ngo, D.-N. Ngo, and T. S. Vo, "Investigation of biological activities of wild bitter melon (*Momordica charantia* Linn. var. *abbreviata* ser.)," *Biomolecules*, vol. 9, no. 6, p. 211, 2019.
- [78] S. Y. Ciou, C. C. Hsu, Y. H. Kuo, and C. Y. Chao, "Effect of wild bitter gourd treatment on inflammatory responses in BALB/c mice with sepsis," *BioMedicine*, vol. 4, no. 3, 2014.
- [79] Z. Z. Hafiz, M. A. M. Amin, R. M. Johari James, L. K. Teh, M. Z. Salleh, and M. I. Adenan, "Inhibitory effects of raw extract *Centella asiatica* (RECA) on acetylcholinesterase, inflammations, and oxidative stress activities via in vitro and in vivo," *Molecules*, vol. 25, no. 4, p. 892, 2020.
- [80] X. Yuyun, C. Xi, Y. Qing, X. Lin, R. Ke, and S. Bingwei, "Asiatic acid attenuates lipopolysaccharide-induced injury by suppressing activation of the Notch signaling pathway," *Oncotarget*, vol. 9, no. 19, p. 15036, 2018.
- [81] L.-N. Zhang, J.-J. Zheng, L. Zhang et al., "Protective effects of asiaticoside on septic lung injury in mice," *Experimental and Toxicologic Pathology*, vol. 63, no. 6, pp. 519–525, 2011.
- [82] J. Wan, L. Yu, X. Zhang et al., "Asiaticoside attenuates lipopolysaccharide-induced acute lung injury via down-regulation of NF- κ B signaling pathway," *International Immunopharmacology*, vol. 26, no. 1, pp. 181–187, 2015.
- [83] L. Zhang, H.-Z. Li, X. Gong et al., "Protective effects of Asiaticoside on acute liver injury induced by lipopolysaccharide/D-galactosamine in mice," *Phytomedicine*, vol. 17, no. 10, pp. 811–819, 2010.
- [84] J. Wan, X. Gong, R. Jiang, Z. Zhang, and L. Zhang, "Antipyretic and anti-inflammatory effects of asiaticoside in lipopolysaccharide-treated rat through up-regulation of heme oxygenase-1," *Phytotherapy Research*, vol. 27, no. 8, pp. 1136–1142, 2013.
- [85] Z. Li, X. Xiao, and M. Yang, "Asiatic acid inhibits lipopolysaccharide-induced acute lung injury in mice," *Inflammation*, vol. 39, no. 5, pp. 1642–1648, 2016.
- [86] W. Cao, X.-Q. Li, X.-N. Zhang et al., "Madecassoside suppresses LPS-induced TNF- α production in cardiomyocytes through inhibition of ERK, p38, and NF- κ B activity," *International Immunopharmacology*, vol. 10, no. 7, pp. 723–729, 2010.
- [87] W. Wang, L. Wu, Q. Li et al., "Madecassoside prevents acute liver failure in LPS/D-GalN-induced mice by inhibiting p38/NF- κ B and activating Nrf2/HO-1 signaling," *Biomedicine & Pharmacotherapy*, vol. 103, pp. 1137–1145, 2018.
- [88] C. Jiang, P. R. Mayeux, T. Nguyen et al., "The endothelium in sepsis," *Shock*, vol. 45, no. 3, p. 259, 2016.
- [89] A. Okhwarobo, J. Ehizogie Falodun, O. Erharuyi, V. Imieje, A. Falodun, and P. Langer, "Harnessing the medicinal properties of *Andrographis paniculata* for diseases and beyond: a review of its phytochemistry and pharmacology," *Asian Pacific Journal of Tropical Disease*, vol. 4, no. 3, p. 213, 2014.
- [90] U. Mishra, A. Mishra, R. Kumari, P. Murthy, and B. Naik, "Antibacterial activity of ethanol extract of *Andrographis paniculata*," *Indian Journal of Pharmaceutical Sciences*, vol. 71, no. 4, p. 436, 2009.
- [91] K. Sheeja, P. K. Shihab, and G. Kuttan, "Antioxidant and anti-inflammatory activities of the Plant *Andrographis Paniculata* Nees," *Immunopharmacology and Immunotoxicology*, vol. 28, no. 1, pp. 129–140, 2006.
- [92] A. Nugroho, N. Warditiani, S. Pramono, M. Andrie, E. Siswanto, and E. Lukitaningsih, "Antidiabetic and anti-hyperlipidemic effect of *Andrographis paniculata* (Burm. f.) Nees and andrographolide in high-fructose-fat-fed rats," *Indian Journal of Pharmacology*, vol. 44, no. 3, p. 377, 2012.
- [93] W.-W. Chao, Y.-H. Kuo, and B.-F. Lin, "Anti-inflammatory activity of new compounds from *Andrographis paniculata* by NF- κ B transactivation inhibition," *Journal of Agricultural and Food Chemistry*, vol. 58, no. 4, pp. 2505–2512, 2010.
- [94] J. Liu, Z. T. Wang, L. L. Ji, and B. X. Ge, "Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E 2 production in LPS-stimulated murine macrophage," *Molecular and Cellular Biochemistry*, vol. 298, no. 1-2, pp. 49–57, 2007.
- [95] J. Liu, Z.-T. Wang, and L.-L. Ji, "In vivo and in vitro anti-inflammatory activities of neoandrographolide," *The American Journal of Chinese Medicine*, vol. 35, no. 2, pp. 317–328, 2007.
- [96] C. V. Chandrasekaran, P. Thiyagarajan, H. B. Deepak, and A. Agarwal, "In vitro modulation of LPS/calcein induced inflammatory and allergic mediators by pure compounds of *Andrographis paniculata* (King of bitters) extract," *International Immunopharmacology*, vol. 11, no. 1, pp. 79–84, 2011.
- [97] J. Liu, Z.-T. Wang, and B.-X. Ge, "Andrograpanin, isolated from *Andrographis paniculata*, exhibits anti-inflammatory property in lipopolysaccharide-induced macrophage cells through down-regulating the p38 MAPKs signaling pathways," *International Immunopharmacology*, vol. 8, no. 7, pp. 951–958, 2008.
- [98] I. Stoilova, A. Krastanov, A. Stoyanova, P. Denev, and S. Gargova, "Antioxidant activity of a ginger extract (*Zingiber officinale*)," *Food Chemistry*, vol. 102, no. 3, pp. 764–770, 2007.
- [99] S. C. Penna, M. V. Medeiros, F. S. C. Aimbire, H. C. C. Faria-Neto, J. A. A. Sertié, and R. A. B. Lopes-Martins, "Anti-inflammatory effect of the hydralcoholic extract of *Zingiber officinale* rhizomes on rat paw and skin edema," *Phytomedicine*, vol. 10, no. 5, pp. 381–385, 2003.
- [100] S. H. Habib, S. Makpol, N. A. Hamid, S. Das, W. Z. Ngah, and Y. A. Yusof, "Ginger extract (*Zingiber officinale*) has anticancer and anti-inflammatory effects on ethionine-induced hepatoma rats," *Clinics*, vol. 63, no. 6, pp. 807–813, 2008.

- [101] A. Z. Amran, I. Jantan, R. Dianita, and F. Buang, "Protective effects of the standardized extract of *Zingiber officinale* on myocardium against isoproterenol-induced biochemical and histopathological alterations in rats," *Pharmaceutical Biology*, vol. 53, no. 12, pp. 1795–1802, 2015.
- [102] D. Mukherjee and R. Ahmad, "COX-2/iNOS regulation during experimental hepatic injury and its mitigation by cloudy apple juice," *International Journal of Biological Macromolecules*, vol. 140, pp. 1006–1017, 2019.
- [103] E. Koh, H. Kim, S. Kim et al., "Modulation of macrophage functions by compounds isolated from *Zingiber officinale*," *Planta Medica*, vol. 75, no. 02, pp. 148–151, 2009.
- [104] M.-H. Pan, M.-C. Hsieh, P.-C. Hsu et al., "6-Shogaol suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages," *Molecular Nutrition & Food Research*, vol. 52, no. 12, pp. 1467–1477, 2008.
- [105] S. Dugasani, M. R. Pichika, V. D. Nadarajah, M. K. Balijepalli, S. Tandra, and J. N. Korlakunta, "Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol," *Journal of Ethnopharmacology*, vol. 127, no. 2, pp. 515–520, 2010.
- [106] S. S. Hong and J. S. Oh, "Phenylpropanoid ester from *Zingiber officinale* and their inhibitory effects on the production of nitric oxide," *Archives of Pharmacal Research*, vol. 35, no. 2, pp. 315–320, 2012.
- [107] F. Li, V. Nitteranon, X. Tang et al., "In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin," *Food Chemistry*, vol. 135, no. 2, pp. 332–337, 2012.
- [108] Y. a. Han, C. w. Song, W. s. Koh et al., "Anti-inflammatory effects of the *Zingiber officinale* roscoe constituent 12-dehydrogingerdione in lipopolysaccharide-stimulated raw 264.7 cells," *Phytotherapy Research*, vol. 27, no. 8, pp. 1200–1205, 2013.
- [109] S. M. Salama, M. A. Abdulla, A. S. AlRashdi, S. Ismail, S. S. Alkiyumi, and S. Golbabapour, "Hepatoprotective effect of ethanolic extract of *Curcuma longa* on thioacetamide induced liver cirrhosis in rats," *BMC Complementary and Alternative Medicine*, vol. 13, no. 1, p. 56, 2013.
- [110] C. Chandrasekaran, K. Sundarajan, J. Edwin, G. Gururaja, and D. Mundkinajeddu, "Immune-stimulatory and anti-inflammatory activities of *Curcuma longa* extract and its polysaccharide fraction," *Pharmacognosy Research*, vol. 5, no. 2, p. 71, 2013.
- [111] I. A. Agarwal, W. A. N. Wan Ahmad, N. S. Ramli, and N. A. Ghafar, "Antimicrobial and antioxidant property of *Curcuma longa* Linn," *International Journal of Basic & Clinical Pharmacology*, vol. 8, no. 11, p. 2383, 2019.
- [112] M. Ichsyani, A. Ridhanya, M. Risanti et al., "Antiviral effects of *Curcuma longa* L. against dengue virus *in vitro* and *in vivo*," *IOP Conference Series: Earth and Environmental Science*, vol. 101, no. 1, 2017.
- [113] C. Chen, L. Long, F. Zhang et al., "Antifungal activity, main active components and mechanism of *Curcuma longa* extract against *Fusarium graminearum*," *P.o.S One*, vol. 13, no. 3, 2018.
- [114] M. Kuroda, Y. Mimaki, T. Nishiyama et al., "Hypoglycemic effects of turmeric (*Curcuma longa* L. rhizomes) on genetically diabetic KK-Ay mice," *Biological & Pharmaceutical Bulletin*, vol. 28, no. 5, pp. 937–939, 2005.
- [115] M. Corrigan, S. S. Wilson, and J. Hampton, "Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings," *American Journal of Health-System Pharmacy*, vol. 72, no. 18, pp. 1544–1554, 2015.
- [116] C. Okuda-Hanafusa, R. Uchio, A. Fuwa et al., "Turmeronol A and turmeronol B from *Curcuma longa* prevent inflammatory mediator production by lipopolysaccharide-stimulated RAW264.7 macrophages, partially via reduced NF- κ B signaling," *Food & Function*, vol. 10, no. 9, pp. 5779–5788, 2019.
- [117] K. Kawasaki, C. Okuda-Hanafusa, M. Aoyagi et al., "Inhibitory effect of the compounds from the water extract of *Curcuma longa* on the production of PGE2 and NO in a macrophage cell line stimulated by LPS," *Bioscience, Biotechnology, and Biochemistry*, vol. 82, no. 12, pp. 2109–2117, 2018.
- [118] C. L. Tham, K. W. Lam, R. Rajajendram et al., "The effects of a synthetic curcuminoid analogue, 2, 6-bis-(4-hydroxyl-3-methoxybenzylidene) cyclohexanone on proinflammatory signaling pathways and CLP-induced lethal sepsis in mice," *European Journal of Pharmacology*, vol. 652, no. 1–3, pp. 136–144, 2011.
- [119] Y. Wang, X. Shan, Y. Dai et al., "Curcumin analog L48H37 prevents lipopolysaccharide-induced TLR4 signaling pathway activation and sepsis via targeting MD2," *Journal of Pharmacology and Experimental Therapeutics*, vol. 353, no. 3, pp. 539–550, 2015.
- [120] C. Zhao, Y. Zhang, P. Zou et al., "Synthesis and biological evaluation of a novel class of curcumin analogs as anti-inflammatory agents for prevention and treatment of sepsis in mouse model," *Drug Design, Development and Therapy*, vol. 9, p. 1663, 2015.
- [121] J. Qian, X. Chen, S. Shu et al., "Design and synthesis novel dicarbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI)," *European Journal of Medicinal Chemistry*, vol. 167, pp. 414–425, 2019.
- [122] M. F. Aluwi, K. Rullah, B. M. Yamin et al., "Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines," *Bioorganic & Medicinal Chemistry Letters*, vol. 26, no. 10, pp. 2531–2538, 2016.
- [123] H. Zhu, T. Xu, C. Qiu et al., "Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats," *European Journal of Medicinal Chemistry*, vol. 121, pp. 181–193, 2016.
- [124] F. Ahmad, G. M. Khan, B. H. Abbasi, S. Farooq, M. Ali, and M. A. Khan, "Study of aging and hepatoprotective activity of *Vitis vinifera* L. Seeds in albino rats," *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 3, pp. S1770–S1774, 2012.
- [125] M. S. Akthar, G. Birhanu, and S. Demisse, "Antimicrobial activity of *Piper nigrum* L. and *Cassia didymobotrya* L. leaf extract on selected food borne pathogens," *Asian Pacific Journal of Tropical Disease*, vol. 4, pp. S911–S919, 2014.
- [126] İ. Gülçin, "The antioxidant and radical scavenging activities of black pepper (*Piper nigrum*) seeds," *International Journal of Food Sciences and Nutrition*, vol. 56, no. 7, pp. 491–499, 2005.
- [127] Y. Deng, S. Sriwiriyan, A. Tedasen, P. Hiransai, and P. Graidist, "Anti-cancer effects of *Piper nigrum* via inducing multiple molecular signaling *in vivo* and *in vitro*," *Journal of Ethnopharmacology*, vol. 188, pp. 87–95, 2016.
- [128] A. M. Nirwane and A. R. Bapat, "Effect of methanolic extract of *Piper nigrum* fruits in ethanol-CCl4 induced hepatotoxicity in Wistar rats," *Der Pharmacia Lettre*, vol. 4, no. 3, pp. 795–802, 2012.

- [129] F. Tasleem, I. Azhar, S. N. Ali, S. Perveen, and Z. A. Mahmood, "Analgesic and anti-inflammatory activities of Piper nigrum L.," *Asian Pacific Journal of Tropical Medicine*, vol. 7, pp. S461–S468, 2014.
- [130] Q. M. T. Ngo, P. T. Tran, M. H. Tran et al., "Alkaloids from Piper nigrum Exhibit anti-inflammatory activity via activating the Nrf2/HO-1 pathway," *Phytotherapy Research*, vol. 31, no. 4, pp. 663–670, 2017.
- [131] H. Pei, L. Xue, M. Tang et al., "Alkaloids from black pepper (piper nigrum L.) exhibit anti-inflammatory activity in murine macrophages by inhibiting activation of NF- κ B pathway," *Journal of Agricultural and Food Chemistry*, vol. 68, no. 8, pp. 2406–2417, 2020.
- [132] D. F. Ye, C. R. F. de Souza, and W. P. Oliveira, "Clove (*Syzygium aromaticum*): a precious spice," *Asian Pacific Journal of Tropical Biomedicine*, vol. 4, no. 2, pp. 90–96, 2014.
- [133] W. L. Nana, P. Eke, R. Fokom et al., "Antimicrobial activity of *Syzygium aromaticum* and *Zanthoxylum xanthoxyloides* essential oils against *Phytophthora megakarya*," *Journal of Phytopathology*, vol. 163, no. 7–8, pp. 632–641, 2015.
- [134] Y. Tanko, A. Mohammed, M. A. Okasha, A. Umah, and R. Magaji, "Anti-nociceptive and anti-inflammatory activities of ethanol extract of *Syzygium aromaticum* flower bud in wistar rats and mice," *African Journal of Traditional, Complementary and Alternative Medicines*, vol. 5, no. 2, pp. 209–212, 2008.
- [135] K.-G. Lee and T. Shibamoto, "Antioxidant property of aroma extract isolated from clove buds [*Syzygium aromaticum* (L.) Merr. et Perry]," *Food Chemistry*, vol. 74, no. 4, pp. 443–448, 2001.
- [136] A. Agarwal, "Antibacterial activity of some plants against drug resistant neonatal sepsis causing bacteria," November 2019, https://storage.googleapis.com/journal-uploads/wjpps/article_issue/1444051044.pdf.
- [137] N. S. Gill, P. Rani, R. Arora, V. Dhawan, and M. Bali, "Evaluation of antioxidant, anti-inflammatory and antiulcer potential of *Momordica charantia* methanolic seed extract," *Research Journal of Phytochemistry*, vol. 6, no. 4, pp. 96–104, 2012.
- [138] S. Thiagarajan, D. J. Arapoc, N. Husna Shafie et al., "Momordica charantia (Indian and Chinese bitter melon) extracts inducing apoptosis in human lung cancer cell line A549 via ROS-mediated mitochondria injury," *Evidence-Based Complementary and Alternative Medicine*, vol. 2019, Article ID 2821597, 9 pages, 2019.
- [139] K. D. Mwambete, "The *in vitro* antimicrobial activity of fruit and leaf crude extracts of *Momordica charantia*: a Tanzania medicinal plant," *African Health Sciences*, vol. 9, no. 1, pp. 34–39, 2009.
- [140] R. Fachinan, A. Yessoufou, M. P. Nekoua, and K. Moutairou, "Effectiveness of antihyperglycemic effect of *Momordica charantia*: implication of t-cell cytokines," *Evidence-Based Complementary and Alternative Medicine*, vol. 2017, Article ID 3707046, 8 pages, 2017.
- [141] B. Joseph and D. Jini, "Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency," *Asian Pacific Journal of Tropical Disease*, vol. 3, no. 2, pp. 93–102, 2013.
- [142] S. R. Shivanagoudra, W. H. Perera, J. L. Perez et al., "In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from *Momordica charantia* L.," *Bioorganic & Medicinal Chemistry*, vol. 27, no. 14, pp. 3097–3109, 2019.
- [143] S. R. Shivanagoudra, W. H. Perera, J. L. Perez et al., "Cucurbitane-type compounds from *Momordica charantia*: isolation, *in vitro* antidiabetic, anti-inflammatory activities and in silico modeling approaches," *Bioorganic Chemistry*, vol. 87, pp. 31–42, 2019.
- [144] P. Hashim, H. Sidek, M. Helan, A. Sabery, U. D. Palanisamy, and M. Ilham, "Triterpene composition and bioactivities of *Centella asiatica*," *Molecules*, vol. 16, no. 2, pp. 1310–1322, 2011 Feb.
- [145] H. Y. Alfarrar and M. N. Omar, "*Centella asiatica*: from folk remedy to the medicinal biotechnology—a state revision," *International Journal of Biosciences*, vol. 3, no. 6, pp. 49–67, 2013.
- [146] S. S. Jamil, Q. Nizami, and M. Salam, "*Centella asiatica* (Linn.) Urban—a review," *Indian Journal of Natural Products and Resources*, vol. 6, pp. 158–170, 2007.
- [147] J.-H. Won, J.-S. Shin, H.-J. Park et al., "Anti-inflammatory effects of madecassic acid via the suppression of NF- κ B pathway in LPS-induced RAW 264.7 macrophage cells," *Planta Medica*, vol. 76, no. 03, pp. 251–257, 2010.
- [148] N. X. Nhiem, B. H. Tai, T. H. Quang et al., "A new ursane-type triterpenoid glycoside from *Centella asiatica* leaves modulates the production of nitric oxide and secretion of TNF- α in activated RAW 264.7 cells," *Bioorganic & Medicinal Chemistry Letters*, vol. 21, no. 6, pp. 1777–1781, 2011.
- [149] D. S. S. M. Uppu, C. Ghosh, and J. Haldar, "Surviving sepsis in the era of antibiotic resistance: are there any alternative approaches to antibiotic therapy?" *Microbial Pathogenesis*, vol. 80, pp. 7–13, 2015.
- [150] H. C. Chen, W. C. Chen, K. H. Lin et al., "Simultaneous use of traditional Chinese medicine (Si-Ni-Tang) to treat septic shock patients: study protocol for a randomized controlled trial," *Trials*, vol. 12, no. 1, p. 199, 2011.
- [151] D. Košťálová, L. Bezáková, L. Račková, S. Mošová, and E. Šturdík, "Therapeutic potential of curcumin in medicinal chemistry," *Acta Chimica Slovaca*, vol. 6, no. 1, pp. 89–99, 2013.
- [152] H. He, W. W. Guo, X. Q. Chen, H. Y. Zhao, and X. Wu, "Comparative metabolism of three amide alkaloids from *Piper longum* in five different species of liver microsomes," *China Journal of Chinese Materia Medica*, vol. 41, no. 16, pp. 3084–3089, 2016.
- [153] M. C. Vasconcellos, R. C. Montenegro, G. C. Militão et al., "Bioactivity of biflorin, a typical o-naphthoquinone isolated from *Capraria biflora* L.," *Zeitschrift für Naturforschung C*, vol. 60, no. 5–6, pp. 394–398, 2005.